Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
4-11-2014 12:00 AM

Development of Non-Covalent Functionalization of Carbon
Nanotubes for siRNA Delivery
King Sun Siu, The University of Western Ontario
Supervisor: Prof. Wei-Ping Mei, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Doctor of Philosophy degree
in Pathology
© King Sun Siu 2014

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Biotechnology Commons, Macromolecular Substances Commons, Medical Biotechnology
Commons, and the Nanomedicine Commons

Recommended Citation
Siu, King Sun, "Development of Non-Covalent Functionalization of Carbon Nanotubes for siRNA Delivery"
(2014). Electronic Thesis and Dissertation Repository. 2006.
https://ir.lib.uwo.ca/etd/2006

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

DEVELOPMENT OF NON-COVALENT FUNCTIONALIZATION OF CARBON
NANOTUBES FOR siRNA DELIVERY
Thesis format: Integrated Article

by

King Sun Siu

Graduate Program in Pathology

A thesis submitted in partial fulfilment
of the requirements for the degree of
Doctor of Philosophy
The School of Graduate and Postdoctoral Studies
The University of Western Ontario
London, Ontario, Canada
© King Sun Siu 2014

Abstract
RNA interference (RNAi) therapy is promising for treating various diseases but the delivery
of small interfering RNA (siRNA) is difficult. To overcome the technical difficulties of
siRNA delivery, an efficient and targeted delivery of siRNA is required for efficient RNAi
therapy. Single-walled carbon nanotubes (CNT) has been used for nucleic acid delivery such
as siRNA delivery. It has been found that CNT can gain entry into the cells by a diffusionlike mechanism which was called “nano-needle”. However, the solubility of CNT is low in
most of the solvents including water. Functionalization of CNT can be carried out to enhance
the solubility of the CNT in water and non-covalent functionalization of CNT is easy to be
carried out. Poly(ethylenimine) (PEI) is a cationic polymer and it has been shown to disperse
CNT in water. Also, it can deliver nucleic acids including siRNA. However, it is not very
efficient at delivering siRNA unless adequately modified.
Three different modifications on PEI were carried out. These polymers and the dispersed
CNT were characterized and siRNA delivery capacities of the CNTs were examined in vitro
and in vivo. The first was lipid-poly(ethylene glycol) (PEG) conjugated PEI. The second
polymer was succinic acid conjugated PEI and the dispersed CNT was used topically in a
melanoma model delivering Braf siRNA. The tumor progression was reduced dramatically.
Following this work, folic acid, a ligand which target cancer cells was conjugated to the PEG
and succinic acid modified PEI. The dispersed CNT was used for systematic delivery of
mTOR siRNA in a melanoma model. The tumor progression was inhibited significantly.

Keywords
CNT, SWCNT, RNAi, siRNA, non-viral gene delivery, siRNA delivery, folic acid, topical
siRNA delivery, melanoma, Braf, mTOR, non-covalent functionalization, PEI, PEG, tumor
siRNA delivery, RNAi therapy, targeted delivery
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Chapter 1

1

Introduction to RNA interference and Carbon
Nanotubes-Based Nucleic Acids Delivery
1.1

Background of RNA Interference

1.1.1 Brief Introduction to Gene Therapy
Gene therapy is the use of nucleic acids to generate therapeutic effect by correcting the
existing abnormality or providing the cells with new functions. The idea of utilizing
genetic materials for therapy is not new, and was proposed by Tatum in 1966 [1]. Virusbased delivery vectors for transferring disease-related gene into mammalian cells were
carried out in the 1970s to 1980s [2]. The first somatic gene therapy protocol in humans
was approved and carried out in 1990. Retrovirus modified tumor-infiltrating
lymphocytes were used for melanoma immunotherapy [3] and retrovirus-mediated
transfer of adenosine deaminase (ADA) gene to the T-lymphocyte was employed for the
treatment of ADA deficiency children [4-9]. Over the past few decades our knowledge of
molecular mechanisms of gene function has increased substantially. The discovery of
RNAi in the late 90s has caught the attention of scientists.

1.1.2 Introduction to RNA Interference
In 1990, Napoli tried to genetically engineer a kind of flower, petunias to produce more
pigment by introducing some extra copies of the gene which encode chalcone synthase,
the pigment producing protein. However, the result showed that the extra copies of the
gene blocked the production of chalcone synthase instead and it was named cosuppression [10]. A similar phenomenon was reported by Krol in the same year [11]. In
1993, micro RNA (miRNA), a non-coding gene for regulating gene expression was
discovered [12, 13]. In 1998, double-stranded RNA (dsRNA) mediated specific RNA
interference (RNAi) which was demonstrated by Fire and Mello in Caenorhabditis
elegans [14]. Later, it was found that these processes shared most of the core components
in gene expression regulation [15]. In 1999, small antisense RNA was described to be the
component which induces the RNAi [16]. Later, this small RNA was found to trigger
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RNAi and was called small interfering RNA (siRNA) [17, 18]. In 2001, RNAi was
observed in cultured mammalian cells [19]. In 2004, the first RNAi-based clinical trial
had been started. It was aimed at treating age-related macular degeneration (AMD) by
intravitreal injection of siRNA-027 by reducing the growth of pathological blood vessels
[20]. In the last decade, the mechanisms of RNAi have become clearer and scientists have
explored the possibility of utilizing it as a tool for research and for therapy.

1.1.3 Principle and Application of RNAi
RNAi is also called post transcriptional gene silencing (PTGS), which is a type of antisense mechanism [21]. It is well-conserved and can be found in plants, viruses,
invertebrates and protozoa [21, 22]. Two major classes of small RNA which induce
RNAi are present, siRNA and miRNA. siRNA is 21-23 nucleotides long and its
sequences are perfectly complementary to the target mRNA [17, 18] while mature
miRNA have 21-23 nucleotides and its sequences are only partially complementary to the
target mRNA [12, 23]. siRNA is endogenous and it usually leads to mRNA degradation
while miRNA usually leads to translational inhibition [24] and sometimes mRNA
degradation [25]. In plants, one of the functions of RNAi is for innate immune defense
against viral infection which produces siRNA to inhibit the translation of viral RNA [26].
siRNA has also been found in mammals and one of their known functions is to suppress
retrotransposition [27, 28]. siRNA is the most important component to induce RNAi [1618, 29] and it can be synthesized and introduced into cells directly. RNAi can also be
induced by the introduction of dsRNA, which is cut into siRNA by Dicer [30]. Another
approach is small hairpin RNA (shRNA) which was designed to produce siRNA. It is an
insert into plasmid construct such that a small fragment of RNA with a stem-loop or
hairpin loop is produced. Then the hairpin loop is cut by Drosha into the designed siRNA
[31, 32]. A brief mechanism of RNAi is as follows. After the dsRNA or shRNA is cut
into siRNA by the Drosha (Step 1), or the siRNA gained into the cells, the siRNA duplex
and DCR2–R2D2 heterodimer forms RNA-induced silencing complex (RISC) loading
complex or RLC [33] (Step 2). Then the complexes load the RNA duplex into the
argonaute protein (AGO2 for mammals) which turn into inactive RISC [34] (Step 3).
The guide strand also named as the antisense strand, which has a complementary

3
sequence to the target RNA, stays in the RLC and the other strand which is called
passenger strand or sense strand is degraded, this forms an active RISC [35, 36] (Step 4).
The siRNA guide strand recognizes the mRNA by a sequence specific manner using
Watson-Crick base pairing (Step 5) and the PIWI domain of the RISC initiates the
mRNA cleavage between 10th and 11th nucleotides from 5’-end counted from the guide
strand [37] (Step 6). The cleaved mRNA is then released and the RISC is recycled to
cleave another copy of mRNA [25] (Step 7). (Fig. 1.1)
synthetic siRNA

Dicer
processing of siRNA
Step 1

Step 2
upload to RLC

siRNA not always
released
RLC

siRNA

Step 3 upload to RISC
Active RISC

Inactive RISC
Step 4
passenger strand removal

Step 7 RISC recycle
Step 5
mRNA recognition
Step 6 target mRNA cleavage
and then diassociation

Figure 1.1 Generlized mechanism of RNAi
The structures for Dicer, RLC, inactive RISC and active RISC are simplified
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Nowadays, numerous research and clinical trials on RNAi therapy have been actively
carried out [38, 39]. On October 2013, there are almost 14500 results for the search of
“RNAi” in PubMed. Unlike conventional gene delivery or therapy, which is gain-offunction, RNAi is loss-of-function. It provides a new approach in research as well as in
treating diseases. As the innate antiviral mechanism in plant, researchers used it as a tool
for understanding and treating virus induced diseased such as HIV, influenza, hepatitis,
transplantation and autoimmune diseases [40-46]. Also, it can be used for treating
diseases which are related to overexpression of a single protein [47] such as Alzheimer’s
disease [48], amyotrophic lateral sclerosis (ALS) [49] and cancer [47, 50]. Various
clinical trials have been carried out aiming at treating various disease like HIV, cancer,
hypercholesterolemia and asthma [39]. One of the notable clinical trials on RNAi therapy
is using siRNA “ALN-PCS” which inhibits PCSK9 synthesis and in turn reduces the
blood concentration of low density lipoprotein cholesterol (LDL-C). Phase I clinical trial
is just finished and it reduced the LDL-C with no major toxicity observed [51].

1.1.4 Advantages and Disadvantages of RNAi
There are a lot of advantages of using RNAi for research as well as for therapy. Firstly,
RNAi can be highly target specific. Cleavage may not result for some mismatches by a
single nucleotide between siRNA and the RNA target [52, 53]. It is a promising tool for
studying the interaction between proteins as well as treating disease induced by gain of
function mutations such as cancer [54, 55]. Secondly, small molecules or biologics are
limited by “undruggable” targets which are possible targets for RNAi [47, 56]. Some of
the interaction of proteins cannot be inhibited by small molecules or biologics but the
protein can be removed by RNAi and thus, the interaction of proteins can be studied. The
screening of small molecules to inhibit a known pathological protein is expensive and
inefficient [57] while RNAi can provide as a powerful alternative to treat diseases if the
target is known. Thirdly, RNAi can be introduced transiently by siRNA or permanently
by shRNA respectively for acute or chronic pathological condition [58]. In theory, a
single treatment could cure chronic disease and the cost of treatment can be reduced
drastically while the technology is still transferrable for curing acute disease like
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conventional drug. A short list of the difference between RNAi and traditional small
molecular drug was listed as below (Table. 1.1).

RNAi

Small Molecule

~15k Da for siRNA, over a

Range from several hundred

million Da for shRNA

Da to a thousand Da

Solubility in Water

Highly soluble

Varies

Stability in circulation

Susceptible to be degraded

Usually stable

Molecular Weight

by nuclease
Target specificity

Higher

Lower

Easy to manufacture

Easy

Can be complicated

Delivery

Difficult

Easy

Table 1.1 Comparision of RNAi and conventional small molecular drug

Every coin has two sides; there are also limitations of RNAi. Firstly, there is an intrinsic
difference between the response of human or mammals and plants or other organisms to
dsRNA. There is interferon response, which is a cytokine for fighting against viral
infection in mammals [59]. It would respond to dsRNA which is longer than 30
nucleotides [60] but even for siRNA which has less than 30 nucleotides, it might also
induce interferon response [61]. Also, activation of toll-like receptors has been reported
[62]. It is becoming clearer that sequences like 5’-r(GUCCUUCAA) or 5’-r(UGUGU)
could induce interferon [63] which can be avoided by dsRNA design. Secondly, there is a
possibility for RNAi to be off target, that is, it might inhibit non-targeted genes. As
mentioned earlier for miRNA in mammals, perfect complementary is usually not
observed. Translational suppression is possible when there is partial complementation of
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the seed region of the guide strand, which are the 2nd to 8th nucleotides counted from 5’end [64] to non-targeted mRNA. It is obvious that the foreign siRNA we introduced
might trigger non-targeted miRNA translational inhibition instead of going through the
designed RNAi pathway. Therefore, careful design and testing on the sequences are
necessary. Thirdly, the way how RNAi, siRNA or shRNA were introduced may saturate
the cellular RNAi machine. siRNA completes with miRNA for RISC, which the RISC
maybe be saturated and the miRNA cannot function for normal gene regulation. Lethality
has not been observed for low dosage of shRNA, however, death of mice was observed
by prolonged exposure to high doses of shRNA [65]. The effect of long term saturation of
the RNAi machinery is largely unknown and transient siRNA or triggered shRNA might
be a better option for therapy before the long term effect was uncovered and fully
understood. Lastly, the delivery of siRNA or shRNA is either potentially harmful or
inefficient, which will be covered in next section.

1.2

Challenges in Nucleic Acid Delivery

1.2.1 Difficulties of Nucleic Acids Delivery
The stumbling block of gene therapy as well as RNAi application is the delivery of intact
nucleic acids into the right place effectively and safely. The delivery of nucleic acids into
mammalian cells, a process called transfection is still difficult. It is obvious that the
human body and its defense mechanism have evolved for millions of years, the entry of
potentially harmful foreign substances as well as foreign genetic materials which might
harm our cells or genome is actively or passively impeded by cellular membrane.
Traditional therapeutic small molecules are usually made up of different structure and
they bind to the protein or pathological components which lead to therapeutic effects.
Also, small molecules can gain entry into the cells by diffusion because of their low
molecular weight (usually lower than 1000 Da) and lipophilicity. Most of them cannot be
degraded easily but by the enzyme in a specific site. In contrast, nucleic acids such as
plasmid DNA, messenger RNA, oligo RNA and siRNA are made up of nucleotides. They
have similar structure and the genetic codes which have to be processed by the cellular
machinery in order to generate the therapeutic effect. They cannot gain into the cells by
diffusion easily because of their high molecular weight. The higher molecular weight the
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nucleic acids are, the more difficult for them to diffuse into the cells. So, lower molecular
weight siRNA which has 21 to 23 nucleotides is easier to be delivered compared to
shRNA which is inserted into a plasmid construct which has thousands of nucleotides. In
addition, they can be degraded easily when exposed to intracellular and extracellular
nuclease [66-72]. One of the biggest barriers for utilizing nucleic acids as drug is to bring
them across the cell membrane.
The calculated length of dsDNA with 20 base pair is 7.5 nm [73] and siRNA should be
similar to dsDNA. However, nucleic acids are polyanion and the cellular surface is also
negatively charged. Spontaneous entry of siRNA into cells is unlikely due to electrostatic
repulsion. The same is true for pDNA or shRNA but they are larger which further hinders
their delivery. The desired function cannot be carried out if the nucleic acids are excluded
from the cytosol [68, 72, 74]. Its function can only be brought out by reaching the right
location: cytosol for RNA and nuclear envelope for DNA.
Although the nucleic acids do not gain entry easily into the cell and carry out our desired
therapeutic function, scientists have endeavored various way to deliver nucleic acids into
the cell [1, 68, 74-76].

1.2.2 Cellular Uptake Mechanism and Cellular Trafficking for NonViral Nucleic Acid Delivery
The cellular uptake mechanism is the most important barrier scientists have to understand
and overcome for efficient non-viral nucleic acid delivery. The cell is a well-guided
biochemical plant which highly regulates the entry of foreign substances. There are
several different routes for the cells to take up a substance and some of the important
routes are phagocytosis, Clathrin-mediated endocytosis (CME), Caveolae-mediated
endocytosis (CvME) and marcopinocytosis (Fig. 1.2). Some of the well-studied
endocytosis routes related to non-viral DNA or RNA delivery are summarized as follow.
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Figure 1.2 Cellular uptake mechanism
The CME is Clarthrin-mediated endocytosis; CvME is Caveolae-mediated endocytosis.
Cholera toxin beta subunit (CTB) and transferrin receptor (TFR) are classical markers for
CvME and CME respectively. There are also different markers like early endosome
antigen 1 (EEA-1) and Rab5 for early endosome, Rab7 is the maker for late endosome.
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There are different inhibitors for studying the cellular uptake pathway like Rottlerlin for
marcopinocytosis; chlorpromazine for CME; methyl-β-cyclodextrin (MbCD), genistein,
Filipin for CvME.
(Created with reference to the review of Xiang et al. [77])
Phagocytosis is exhibited by some specialized cells such as macrophages, dendritic cells,
mast cells, monocytes and neutrophils [78]. It is usually for bacteria after opsonization
[79]. Sizes up to 10 µm have been reported which can be taken up by phagocytosis [80]
while 3 µm was reported as the most efficient [81]. It can be exploited as a targeted
delivery method to cells exhibiting phagocytosis like antigen presenting cells [82] and
macrophages [80].
Clathrin-mediated endocytosis is the most well-characterized pathway and a lot of
nanoparticles were designed for cellular uptake by this pathway [83]. It is one of the most
important routes for the internalization of nutrients [84]. This route is exploited by a lot
of viruses for cellular entry [85]. The maximum size of Clathrin-mediated endocytosis
reported was around 200 nm [86].
Caveolae-mediated endocytosis is the most studied clathrin-independent endocytosis
mechanism. It is one of the lipid rafts, which is a combination of sphingolipids,
cholesterol and sometimes glycosphingolipids (GPI) linked protein with the exclusion of
unsaturated lipoprotein to form a denser outer membrane leaflet of cell membranes [87].
This route is also exploited by viruses for cellular entry [88]. The size of caveolaemediated endocytosis observed with TEM was around 70-100 nm [89, 90]. Caveolaemediated endocytosis has been observed in most cells especially endothelial cells and
adipocytes [87].
Marcopinocytosis is a signal dependent process and usually macrophages or cancer cells
exhibit it [77] when there is activation of receptor tyrosine kinases like epidermal growth
factor receptor (EGFR) or platelet-derived growth factor receptor (PDGFR). It has a
diameter greater than 0.2 µm and most of the studies on it are related to antigen
presentation [91].
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After endocytosis, the components are engulfed in phagosome or early endosome which
is topologically outside the cell. The nucleic acids still cannot function because of the
partition of endosome or phagosome. For early endosome, it will be transferred to later
endosome and later lysosome for endosome and phagosome. The content inside is then
degraded [92]. The escape from the endosome or late endosome is therefore necessary
[93]. The pH reduces to facilitate the action of degrading enzymes from endosome to
lysosome [92]. Additionally, caveolae-mediated endocytosis uptake will lead to
caveosome which has a neutral pH [94].
There are three major mechanisms for delivery vectors to efficiently escape from the
endosome or lysosome: flip-flop, proton sponge and expanded umbrella. The flip-flop
mechanism is mostly exhibited by liposome. It was predicted by a computational model
[95] and later confirmed by Xu et al [96]. The lipid of liposomes interact with the lipid in
cell membrane and because of the pH sensitive lipids, the liposome flip-flop from the
lamellar phrase to inverted hexagonal phrase [97] which was also observed under cryoTEM by changing the temperature of the lipid [98, 99].
Proton sponge effect, the exceptional transfection capacity by polyethylenimine (PEI)
was hypothesized by Behr. Amine groups in PEI neutralized the proton in endosomes by
its wide buffering range (pH 3-10). Chloride anions gain entry into the endosome because
of the charge balance and water gains into the endosome by water potential. The
PEI/DNA complexes are then released due to the rupture of the endosome by the
accumulated osmotic pressure [100]. This hypothesis was supported by computational
model [101, 102] but it is still controversial due to various methods of observing or
examining the proton sponge effect [103-106]. This hypothesis was also used for
explaining the exceptional transfection capacity of non PEI vectors [107, 108].
Expanded umbrella is the extended version of proton sponge hypothesis. The influx of
proton neutralized by the basic polymer again but the originally flexible complex
(polymer/DNA complexes) expanded and extended due to the repulsion between the
positively charged polymer chains. The endosome burst because of the rigid polymer by
increased volume and space [109].
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Cell penetrating peptide (CPP) or protein transduction domain (PTD) is another
important class of materials which is known to facilitate endosomal escapes or directs
cell penetration [108, 110]. Some reported that CPP can mediate both at the same time
[111]. The first CPP discovered was Trans-Activator of Transcription (Tat) peptide,
which is derived from HIV-1 [112]. Some well-studied CPP are pennetratin, derived from
the third helix of Antennapdeia homeodomain [113]; oligoarginine, the many arginine
domain developed from Tat [114-116]; GALA, a peptide derived from virus protein
which was synthesized for interacting with cellular membranes [117], transportan which
is a chimeric peptide of galanin (a peptide from G protein-coupled receptors mainly
found in central nervous system) and Mastoparan (peptide of wasp venom) [118, 119],
pVEC peptide [120] and tryptophan rich peptide derived from pVEC [121] and more
[108, 110, 122]. Some of the proposed mechanisms for the “cell penetrating” properties
are inverted micelle formation [123, 124], pore-formation [125-127] and adaptive
translocation [128, 129]. Indeed, various mechanisms are proposed and some of them
enter the cell via multiple pathways including energy dependent endocytotic pathways
[129-131].
After the escape from the endosome, the sites of delivery for different nucleic acids
(RNA or DNA) are different. For RNA delivery, introduction of RNA to cytosol or
siRNA to processing bodies (P-bodies) are good enough for the RNA to carry out the
desired function while for DNA delivery, the DNA has to enter the nucleus for
transcription into mRNA or shRNA followed by translation or further processing in
cytosol. Two possible pathways could be involved for the nuclear entry of DNA. The first
one is the release of DNA from complexes to cytosol and the DNA gains entry into the
nucleus. This is similar to injection of naked DNA into cytosol. Alternatively, the
complexes can transport near the nucleus by microtubules and then release the DNA or
are directly transported into the nucleus. Some complexes can be transported actively to
the nucleus [132] which is believed to be more efficient for DNA delivery since DNA
molecules longer than 2000 base pairs are immobile in the cytosol [133]. Also, the DNA
needs to be protected from nuclease degradation in the cytosol by the complexes before it
reaches the nucleus [134]. Furthermore, DNA usually has a size larger than 10 nm which
is the size limit for passive diffusion through the nuclear pore complex (NPC) in
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interphase [135]. If the cell is undergoing mitosis, DNA can get into the nuclear complex
as the nuclear membrane disassembles [136]. However, most of the cells are not
undergoing mitosis and efficient nuclear entry is necessary. Nuclear localization signals
(NLS) maybe used to facilitate nucleus entry [137, 138]. This can extend the NPC up to a
diameter of 26 nm or 8 million Da in different stages in cultured cell [139].

1.2.3 Overview of Nucleic Acids Delivery Methods
There are two main approaches which can be used for nucleic acid delivery, physical
methods and non-physical methods. Physical methods are the use of the physical means
to deliver nucleic acids into cells such as intra-muscular injection of naked plasmid DNA
or siRNA, gene gun, massage, sonication, hydrodynamic injection and electroporation [1,
74, 140-142]. Non-physical methods included the use of viruses [143-149], bacteria
[150], chemically modified nucleic acids for siRNA [151], chemicals [152-154],
exosome generated by cells [155], fragment antigen-binding [156] to facilitate the
delivery of nucleic acids. The reagents for delivering nucleic acids are also called
“transfection vector” or “vector”. Based on convention, there are two types of vectors,
viral and non-viral.

1.2.4 Limitation of Viral Vectors
Viruses are a biological agent that carry nucleic acids and have evolved to equip effective
methods to evade host immune response and replicate themselves by utilizing the cellular
materials, and often hijacking the cellular machinery. They are the expert in delivering
nucleic acids. Various viruses have been used in both research and clinical trials such as
retrovirus, lentivirus, adenovirus, adeno-associated virus and herpes simplex virus [157164]. In general, viral vectors are highly effective and they have been used in clinical
trials in treating various diseases such as cystic fibrosis (CF) [2, 8, 9, 165]. However, as
many researchers have suggested, it suffers from the following disadvantages [1, 2, 8, 9,
68, 166]. Firstly, it induces immune response and resistance such that second
administration will become less effective. Secondly, it might induce insertional
mutagenesis such as turning on oncogenes or turning off anti-tumor genes. Leukemia-like
illness has been developed due to insertional mutagenesis by retrovirus in clinical trials
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[167, 168]. Thirdly, the choice of therapeutic gene is limited because it has limited size
for loading genetic materials. Fourthly, it is difficult to produce and purify large amounts
of viral vectors with consistent quality compared to chemicals. Moreover, contaminations
with a few copies of wide type virus or virus which has the capacity to reproduce itself
might lead to serious consequence to patients. Finally, inflammatory response by innate
immune system to viral vector could lead to lethality. The first death in clinical trials was
due to acute inflammatory response [169]. Although safety concerns might not abandon
the idea of using highly effective viral vector, researchers are exploring safer and
efficacious alternatives delivery vectors.

1.2.5 Overview of Non-Viral Vectors
An ideal vector or so-called “artificial virus” should be safe, easy and cheap to be massproduced, have low or no toxicity to normal cells, be non-immunogenic, be stable during
storage, have a reasonably long half-life in physiological conditions, be eliminated from
body after administration, be able to access targeted cells or tissues, deliver the genetic
materials to induce the desired therapeutic effect and does not induce genetic mutation.
Inorganic nanostructures, proteins, lipid-based, polymer-based vectors and various nanosize materials such as gold nanoparticles or silicone have been used as gene delivery
vectors [74, 166, 170-176]. Notably liposome using a neutral helper lipid 1,2-Dioleoylsnglycero-3-phosphatidylethanolamine (DOPE) [177] could largely enhance the
transfection. Also, a cationic polymer poly(ethylenimine) (PEI) is highly effectively in
delivering pDNA by the “proton sponge” effect [178]. Carbon nanotubes (CNT) have
attracted the interest of researchers for nucleic acids delivery because they can gain entry
into the cells by a diffusion like mechanism as well as by endocytosis [179, 180].

1.2.6 Poly(ethylenimine) (PEI) for Nucleic Acid Delivery
There are two kinds of poly(ethylenimine) (PEI), branched PEI (b-PEI) [181] and linear
PEI (l-PEI) [182]. They are water soluble, basic and positively charged in physiological
pH. b-PEI has a primary, secondary and tertiary amine ratio of 1:2:1[183]. However, the
commercially available b-PEI may not have the primary, secondary and tertiary amine
ratio equals to 1:2:1 but 1:1:1 as suggested by the studies of von Harpe et al.[183]
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PEI (Mw 800 kDa) has been introduced for pDNA delivery by Boussif et al. since 1995
[178]. According to Abdallah et al., PEI can form polyplex with pDNA that produces
transgene expression levels comparable to lentiviral or adenoviral vectors via direct brain
injection [184]. Twenty five kDa (Mw 25000, Mn 10000) and higher molecular weight
PEI has high sufficient transfection efficiency [185], however, their cytotoxicities are
also much higher than low molecular weight PEI [186, 187].
PEI is the gold standard in pDNA delivery because of its high transfection efficiency,
however, it is not very efficient in delivering siRNA both in vitro and in vivo [188-190].
It is believed that the interaction between PEI and siRNA is weaker than PEI and pDNA
and as a result, the protection of siRNA by PEI is too weak and the siRNA was released
after reaching the cell membrane especially for l-PEI [191]. PEI modified by PEG [192,
193], neutral or anion head groups [189] and hydrophobic moiety [194] could mediate
better siRNA delivering capacity compared to unmodified PEI.

1.3

Background of Carbon Nanotubes

1.3.1 Introduction to Carbon Nanotubes
CNT, together with graphite, diamond, graphene and buckminsterfullerene are a class of
carbon allotrope (Fig 1.3). They were a class of nano-size materials first discovered in
1952 by Russian scientists Radushkevich and Lukyanovich, described again by Bollmann
and Spreadborough in 1960 and then described in 1976 by Oberlin, Endo and Koyama
[195, 196]. Finally, they were rediscovered by Iijima in 1991 and they have been caught
by the attention of scientists [197]. CNT are seamless cylinders of graphene sheets. There
are two kinds of CNT, single-walled carbon nanotubes (SWCNT) and multiple-walled
carbon nanotubes (MWCNT). The diameter of the CNT could be up to 100 nm and the
length could be up to centimeter [198-200]. The carbons in the CNT are sp2 hybridized
and most of them are in a six member ring. There are usually defects on the CNT such as
pentagon-heptagon defect (or Stone-Wales rearrangement) or “elbow connection”
between armchair and zigzag confirmation. They could be produced by arc discharge,
chemical vapor deposition, flame and laser ablation [200]. They have three
conformations based on symmetry: armchair, chiral and zigzag (Fig 1.4). They have
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distinct mechanical, electrical, piezoelectric and optical properties. Various applications
of CNT were proposed such as electronic components, sensors, fuel cells, fibers, biomaterials, drug delivery, catalysis and gaseous storage [200-208].

Carbon Nanotube Fullerene
Figure 1.3 Carbon Allotropes

Figure 1.4 Structure of Carbon Nanotubes

Graphene
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1.3.2 Physical and Chemical Properties of CNT
CNT are black solids and they tend to form bundles in solid state due to strong van der
Waals interaction. This is one of the biggest hurdles in CNT modification. Also, they do
not dissolve well in any organic or aqueous solvent. They can be dispersed in some
solvent with sonication, but they precipitate immediately after the sonication is ceased.
However, they interact with various classes of compounds, which could facilitate the
processing of CNT. The three main approaches of CNT modification can be categorized
as follows: 1) covalent modification on the π-conjugated surface of CNT; 2) non-covalent
adsorption or wrapping of molecules on the CNT surface; 3) endohedral filling of the
internal cavity of CNT [209].
Covalent modification include halogenation [210], hydrogenation [211], cycloadditions
[211-213], radical additions [214], nucleophilic additions [215], electrophilic additions
[216], ozonolysis [217, 218], plasma activation [219], addition of inorganic compounds
[220], mechanical functionalizations [221], polymer grafting [222, 223], defect site
reactions [224] and biomolecule or biocompatible molecule attachment [225-233]. Noncovalent modification included the use of polynuclear aromatic compounds [234, 235],
epoxy composites [236], acrylates [237], hydrocarbon polymers [238], conjugated
polymers [239, 240], other synthetic polymers [241-247] and biomolecules [248-253].
Endohedral filling included fullerenes [254, 255], metals [256-258], liquids [259] and
biomolecules [260-262].

1.3.3 CNT and Biological System Interaction
In molecular dynamics simulation, DNA oligonucleotides can be inserted into CNT in
aqueous medium [263]. Also, CNT could be filled with small proteins [260]. These
discoveries have led us to a new realm of nanomaterial and biological system
interactions, such as application of CNT for biosensors [233, 247, 264] or drug delivery
[265-271]. Xiao et al. used acid treated CNT for coupling with hexamethylenediamine
and then reacted to FITC for the study of CNT interaction with cells [272]. Kam et al.
used a lipopolymer to disperse the CNT for cancer therapy [273]. Interestingly, it has
been shown that the cellular uptake of functionalized CNT is energy independent process
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and is independent of cell type [180]. It was coined as “nano-needle” because the CNT
gain into the cells by an orthogonal position [274]. More interesting, both of the
functionalizations were done with 1,3-dipolar cycloaddition of azomethine ylides [180,
275]. On the contrary, some researchers reported that the cellular uptake of f-CNT is an
energy dependent process [223]. The discrepancies between cellular entry mechanisms
are probably due to the different methods of CNT functionalization. Also, the type,
length, aggregation of CNT as well as the cell type tested played an important role on the
cellular uptake mechanism [276, 277]. Bundled CNT and CNT longer than 1 µm would
be taken up by the cell by phagocytosis. For singly dispersed CNT, it can gain entry into
the cells if it is shorter than 1 µm, however, if it formed supermolecules, it will gain entry
into cells by endocytosis (Fig. 1.5). Interestingly, it has been shown that CNT can be
eliminated from cells and body by three different methods of functionalization as
mentioned above [277-279].

Figure 1.5 Parameters influencing the carbon nanotube internalization mechanisms.
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1.3.3.1

CNT Toxicity

The toxicity of CNT is highly controversial. Some researchers have reported the toxicity
of CNT [280-283]. Some researchers have reported the biocompatibility of CNT [284288]. These contradictory reports are probably due to purity of CNT [289], method of
CNT dispersion [290], dosage and assessment method [288, 291, 292]. The presence of
impurities such as metal or metal oxide catalyst residues in CNT would misestimate the
CNT toxicity [288, 292]. Also, pristine CNT (p-CNT) are not soluble in water and thus
the toxicity of CNT in solution can only be determined with functionalization or the
application of surfactants [293, 294]. Some of the surfactants are toxic themselves and
thus it is necessary to do the experiment carefully whether the toxicity is due to the
surfactants residue [293], undissolved CNT, the functionized CNT or CNT themselves.

1.3.3.2

CNT as Nucleic Acid Delivery Vector

The first report of using CNT for pDNA delivery into cells was by Pantarotto et al [274].
Amine functionalized SWCNT was used for the delivery and it exhibited 10 times greater
transfection capacity than naked pDNA. Another approach by Liu et al. [223], used
polyethylenimine grafted MWCNT for pDNA delivery. The transfection capacity was
found to be better than PEI alone. Since then, various functionalized CNT were used to
deliver nucleic acids in vitro and in vivo [268, 273, 295-300]. For covalent
functionalization, two major methods have been used: amination or polymer conjugation.
Direct amination can be done by 1,3-dipolar cycloaddition of azomethine ylides [274] or
acid functionalization followed by conjugation with diamine [298]. Polymer conjugation
was carried out by polymer-graft-type method like grafting to [267, 301-303] and
grafting from [223] approach.
Non-covalently functionalized CNT which could effectively deliver siRNA has also been
developed. Some of the methods [297, 299, 304] were based on Kam’s method [295] by
using a lipopolymer DSPE-PEG for CNT dispersion while some methods were based on
the aromatic π- π stacking interaction [301, 305]. The lipopolymer method exploits the
hydrophobic tail to interact with the CNT hydrophobically while the PEG helps to
disperse the whole complex in water [295] and acts as a site for siRNA covalent
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conjugation by disulphide bonds. This approach is easy to carry out and is highly
efficient. Liu used this method and he delivered siRNA to T cells [304]. This method was
further developed by Cai as an efficient magnetic CNT spearing [297] for in vitro
transfection in T and B cells [297, 299]. Non-covalently dispersed CNT conjugated to the
pDNA directly or condensed by DSPE-PEG-poly(L-lysine). The CNT was filled with
nickel at the end to exhibit magnetism.

1.4

Non-Viral siRNA Delivery in vivo

The delivery of nucleic acids in vivo is important but difficult. The biggest hurdle is the
bioavailability of nucleic acids is usually too low to induce therapeutic effect for
systematic administration [76, 306]. Local administration to the pathological site can be
carried out to increase the bioavailability while there are various methods to improve the
bioavailability of nucleic acids to pathological tissues.

1.4.1 Local Administration
Local administration is a direct and effective way to delivery therapeutics to pathological
tissues or cells. There are various barriers for local administration for nucleic acid
delivery [307]. Depending on the location of pathological tissues or cells, some of them
can be overcome by injection [308], topical application [309], iontophoresis,
electroporation [310] or sonoporation [311]. Topical application for transdermal delivery
is one of the most promising methods due to ease of administration and transdermal
delivery of siRNA has been demonstrated [312, 313].

1.4.1.1

Transdermal Delivery

Topical application of therapeutics is an attractive strategy for treating cutaneous
pathological conditions. This is because its non-invasiveness, ease of self-administration,
selective targeting to pathological location and lower dosage and systematic toxicity for
achieving the therapeutic effect. However, the skin acts as the hurdle for topical delivery.
It is obvious that the skin serves as the first line of defense and it prevents most physical
and chemical insult as well as biological invasions. Traditionally, skin was divided into
three layers: epidermis, dermis and subcutaneous layer.
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The outermost layer of skin is epidermis which has five layers, from outermost to
innermost: stratum corneum (SC), stratum lucidum, stratum granulosum, stratum
spionsum and stratum germinativum. Cells in stratum germinativum contain keratinocyte
which is actively undergoing mitosis. They replicate themselves actively moving
upwards towards the outer layers. The cells in stratum spinosum begin to differentiate
into keratinocytes and their shape change from columnar to polygonal. The keratinocytes
in stratum granulosum are undergoing apoptosis and losing their nuclei. In stratum
corneum, the keratinocytes are highly keratinized and finally differentiate into anucleated
corneocytes [314, 315]. There are 10-30 layers of continually shedding stacks of dead
cells which is 10-20µm thick and is mechanically stiff [316]. The SC is made up of 7585% protein and 5-15% lipids in dry weight [317] (Fig. 1.6a).
The dermis layer is 3-5 mm thick and it has blood vessels, lymph vessels, nerve endings,
sense receptors, hair follicles, sebaceous glands and sweat glands (Fig 1.6b).
Topical therapeutics are mostly excluded by the epidermis, while the SC is the stumbling
block for transdermal delivery [315, 318]. The transdermal delivery effectiveness is
determined by several factors such as the level of hydration of skin, pH, size of molecule,
charge, hydrophilicity, lipophilicity, melting point, the rate of skin renewal and the
thickness of the skin [315].
Transappendageal pathway is the first known pathway for transdermal delivery. It is
because of the presence of natural openings of skin like sweat glands, sebaceous glands
and hair follicles. It is a relatively limited route because these openings constitute only
0.1% of the total skin surface area [314]. Transepidermal pathway can be subcategorized
into two pathways: intercellular route and transcellular route. Intercellular route is the
continuous diffusion of drug through the lipid domains of the cells. Transcellular route is
the diffusion of drug across corneocytes and intercellular lipid lamellae [315].
Transdermal siRNA delivery was carried out by Ritprajak [313] with an emulsion while
Lin carried out transdermal siRNA delivery by the aid of peptide [312].
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Figure 1.6 Structure of skin.
(A) Layers of the epidermis: basal layer, stratum spinosum, stratum granulosum and the
stratum corneum (SC). Cells
ells found in this layer of skin are keratinocytes with different
differentiation levels, Langerhans cells and melanocytes. (B) Skin layers: (1) hypodermis,
dermis containing blood vessels; (2) lymph vessels; (3) nerve endings;; (4) sense
receptors; (5) hair follicles; (6) sebaceous glands and sweat glands and epidermis. (Made
with reference to Pegoraro et al. [315])

1.4.2 Systematic Administration
Systematic administration is one of the best ways to delivery therapeutics to internal
organs. For DNA or siRNA delivered with vectors, one of the most important things is
the colloidal stability of the vector/nucleic acid complexes. The vector/nucleic acid must
exhibit a reasonable long half
half-life
life which is stable in circulation such that the nucleic acids
can be delivered. The vector/nucleic acid complexes must not aggregate in physiological
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salt concentration or in the present of serum protein
protein. Besides, there
here are several other
concerns for systematic delivery because of the more complicated in vivo environment.
First, there is active RNase and DNase such that protection of the siRNA or DNA is
necessary. Second, there is reticuloendothelial system (RES), in which macrophages,
macrophages and
the liver and spleen will take up most of the particle
particles introduced. Third,, naked siRNA
will be excreted because its molecular weight falls below the size of renal clearance.
Therefore, the delivery vector should be able to increase the serum stability, reduce the
interaction
ction between RES and increase the circulation half-life and thus, the bioavailability
of DNA as well as siRNA can be increased and they can reach the cells, gain entry into
the cells and carry out the desired function (Fig 1.7).

Figure 1.7 Barries for pDNA
pDNA/shRNA delivery and siRNA delivery
There are different barriers for different nucleic acids. (a) The barriers for pDNA/shRNA
are more than (b) siRNA because of the necessity of nuclear import for DNA.
DNA Endosomal
or lysosomal escape are usually required if tthe
he vector/DNA or vector/siRNA complexes
were taken up by endocytosis.

1.4.2.1

Poly(ethylene glycol) (PEG) for in vivo Delivery

The conjugation of poly(ethylene glycol) PEG or PEGylation is one of the most
commonly used modifications for in vivo application. Large particles or particles which

23
are highly charged tend to be eliminated by the RES [319]. Also, positively charged
particles will tend to aggregate with serum protein. To reduce the interaction between the
delivery vehicles and RES or serum protein, a shielding domain is needed for in vivo
application. Researchers have attached PEG to various vehicles [320]. The zeta potential
of the resulting complexes can also be reduced but the colloidal stability was maintained
by steric effect [321] and the interaction between immune system [322, 323] or serum
protein can also be reduced due to reduction of positive zeta potential. It outperforms
other polymers not only because of its commercial variability, but also its versatility.
Liposome vectors [324] and even adenovirus [325] have been modified by PEG. Also,
various structure of PEG can be made, block copolymer [326], alternate block copolymer
[327] and graft copolymer [328] have been synthesized. The difference of molecular
weight of PEG, grafting density to PEI and the relationship between biological activities
for pDNA transfection have been compared by Petersen et al [329]. Generally,
PEGylated copolymers reduce toxicity and prolong blood circulation half-life. It is
desirable for in vivo application. However, it is important to note that PEG is
biocompatible but not biodegradable. If the molecular weight of PEG is higher than 30
kDa, it may be retained in our body for a long time as it excesses the limit of renal
elimination of water soluble polymer [169, 330]. Lower molecular weight PEG or
degradable counterpart should be used for clinical application.

1.4.2.2

Ligands

Peptides, antibodies, steroids or other molecules with known biological activities that can
facilitate transfection can be incorporated. It is a desirable method as the bioactive
ligands can be chosen for different desired targets as well as applications [331-338].
Incorporating endogenous ligands is one of the most attractive strategies to increase
transfection efficiency as well as tissue or cell type specificity for systematic delivery.
Because they have high affinity with the receptors expressed on the cell surface, the
vector may gain entry into the cell by receptor-mediated endocytosis. This strategy has
been proved useful by Wanger et al. with transferrin conjugated PLL [339]. Various
receptor specific endogenous ligands have been attached to delivery vehicle [331, 332,
340]. Notably, transferrin [331], folic acid [332], RGD peptide [333, 334], epidermal
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growth factor [338], galactose [335] and mannose [341] as well as many other
endogenous ligands have been used [68]. Some of the cells or tissues express certain
receptors on their cell surface. For example, overexpression of folate receptors [342, 343]
and epidermal growth factor receptors [344] have been detected in various cancer and
cancer cell lines. Therapeutic nucleic acids can be delivered selectively or specifically
with the aid of the endogenous ligand of the vector. This is preferable especially for
delivering suicide genes for cancer therapy so that the therapeutic effect can be
maximized and the damage to the healthy tissues can be minimized.
Some peptide ligands such as nuclear localization signaling peptide (NLS) [345] and CPP
[346] have also been attached to delivery vehicle. These ligands also increase the
transfection efficiencies by the virtue of the known biological activities of the peptides.
However, some of them are derived from viral protein such as HIV1 TAT [347], they
may induce undesirable immune responses. Also, conjugation of these viral proteins is
expensive and the shelf life of storage could be reduced.

1.4.2.3

Folic Acid for Cancer Targeting

Folic acid is a water soluble vitamin. It is an aromatic compound that was first isolated
from spinach in 1941 and was synthesized in 1943 [348]. It is composed of a pteridine
ring, para-amino benzoic acid and glutamic acid (Fig 1.8). It is important for the
synthesis of DNA. There are receptors that bind to folate (anion of folic acid) with high
specificity. Folate receptor is glycosylphosphatidylinositol (GPI) membrane glycoprotein.
It has a very high affinity toward folate, the association constant is 0.1-1 nM [349]. It was
found to be overexpressed in various cancers and cancer cell lines [343, 350]. The high
specificity of folate receptor as well as high expression level in cancer renders it as a
maker of certain cancers [349]. The incorporation of folic acid is not limited to non-viral
gene therapy but also to diagnosis and chemotherapy for cancer [349, 350].
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Figure 1.8 Structure of folic acid

1.5

Braf and mTOR in Cancer

1.5.1 Brief Introduction to Braf in Cancer
Proto-oncogene B-Raf (Braf
Braf) was discovered in 1988 [351]. It belongs to the Rapidly
Accelerated Fibrosarcoma ((Raf) family and v-Raf was the first identified member [352].
v-Raf is the mutated homolog of Raf-1 or C-Raf [353], there is also A-Raf
Raf but its
function has not been well characterized
characterized. A-Raf
Raf was suggested to stabilize Craf/Braf
heterodimer. Raf is serine/threonine
serine/threonine-protein
protein kinase and they play an important role in
Ras-Raf-MEK-ERK cascade of mitogen activated protein kinase (MAPK) pathway. Braf
was identified as the mutational target in various human cancers [354]. The mostly
observed point mutation of Braf in cancer is valine at position 600 from N terminus
changed to glutamine acid residue (V60
(V600E) [355]. It constitutes 90%
% of Braf mutations
and this mutation was found in 27%
27%-70% of malignant melanomas, 36%--53% of
papillary thyroid cancers and 5%-22% of colorectal cancers and ~30% of serous ovarian
in human [356]. Most of the researches in Braf focus on melanoma. In cell culture, Raf
regulates MEK which regulates ERK, which regulates cell proliferation, migration and
apoptosis [357]. The mutated Braf (V600E, originally documented as V599E) has a 500500
fold higher kinase activity compared to the normal Braf [358].. However, the activation of
ERK has also been shown by the heterodimer of Craf/Braf which involve a different
pathway for normal and mutated Braf [359, 360]. Although the patient response of Braf
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inhibitor in clinical trial is exciting, the resistance of Braf mutant inhibition has been
observed in clinical trials [361-363]. The mechanism of Braf resistance has been actively
carried out and various mechanisms have been uncovered [364-368].

1.5.2 Brief Introduction of mTOR in Cancer
Mammalian target of rapamycin (mTOR) is a serine/threonine kinase, which belongs to
the phosphatidylinositol 3-kinase-related kinase (PIKK) protein family. Rapamycin is an
anti-fungal macrolide found in Streptomyces hygroscopicus bacteria [369]. Rapamycin
binds to 12 kDa FK506-binding protein (FKBP12) and the domain that interacts with
rapamycin is called FKBP12-rapamycin binding domain (FRB). Rapamycin inhibits
mTOR and it was found that it can induce cell cycle arrest which suggest that mTOR is
important in regulating cell growth and proliferation [370, 371]. Since then, researchers
focus on the function of mTOR and it was also found to regulate metabolism, survival,
protein and lipid synthesis and autophagy [372]. mTOR interacts with other proteins to
form two functionally different complexes called mTOR complex 1 (mTORC1) and 2
(mTORC2). Both mTOR complexes contain the mTOR kinase, DEPTOR, mammalian
lethal with sec-13 protein 8 (mLST8) [373], DEP domain containing mTOR-interacting
protein (DEPTOR) [374] and Tti1/Tel2 complexes [375]. The unique protein in
mTORC1 are the regulatory-associated protein of mammalian target of rapamycin
(raptor) [376] and proline-rich Akt substrate 40 kDa (pras40) [377] while mTORC2 has
rapmycin-insensitive companion of mTOR (rictor) [378], stress-activated map kinasinteracting protein 1 (mSin1) [379] and protein observed with rictor 1 and 2 (protor 1/2)
[380].
mTORC1 is better characterized and is sensitive to rapamycin. It is downstream of the
PI3k-Akt pathway which is dysregulated in a lot of cancers and most of them are related
to phosphatase and tensin homolog (PTEN) mutation. PTEN inhibits Akt signaling by
dephosphorylating the Akt stimulating phosphatidylinositol (3,4,5)-triphosphate (PIP3)
[381]. Akt is a regulator of metabolism, survival, apoptosis, growth and proliferation
which plays an important role in tumor survival and drug resistance [382, 383].
Upregulation of Akt could lead the phosphorylation of tuberous sclerosis complex 2
(TSC2) which is the negative regulator of mTORC1 [384]. TSC1/2 regulates Ras
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homolog enriched in brain (Rheb) which has GTPase activity and Rheb can interact and
activates mTORC1 [385]. mTORC1 phosphorylates and activates S6K which regulates
cell size, protein translation and cell proliferation [386].
mTORC2 is originally thought to be rapmycin insensitive however, prolonged treatment
of rapamycin reduces mTORC2 signaling in some cells by suppressing the mTOCR2
assembly [387]; the reason is still unknown at the moment. mTORC2 phosphorylates and
activates Akt [388].

1.6

Objective of the Study

siRNA is an effective method to downregulate specific gene expression, however, the
delivery of siRNA is the stumbling block for its clinical application. The “nano-needle”
property of CNT offers a new possibility for drug delivery as well as siRNA delivery.
The degree and the site of modification are important factors for determining the
transfection capacity of the resulting CNT. The reported CNT which exhibit the “nanoneedle” property was functionalized by 1,3-dipolar cycloaddition of azomethine ylides, 1
in 100 carbons were functionalized throughout the CNT [389]. In contrast to the acid
functionalization of CNT, only the side wall and opening of CNT were functionalized,
the side wall with an intact wall can be functionalized.
However, covalent functionalization of CNT is difficult and non-covalent
functionalization is easier to be carried out and it was demonstrated by Kam [295], who
used DSPE-PEG to disperse to CNT non-covalently to deliver siRNA. This CNT
exhibited high transfection capacity in T cells in vitro which is difficult to be transfected.
However, here are several limitations on this design. First of all, the siRNA has to be
further modified, which would increase the cost of manufacturing. Secondly, the exact
amount of siRNA loading has to be determined every time after the conjugation. Thirdly,
the CNT will bear net negative charge due to the attachment of siRNA on the surface
which reduces the transfection capacity. Moreover, if siRNA is not bound to a surface or
electrostatically condensed, they might still be accessible for RNase or DNase. The
degree of degradation is unknown and siRNA degradation was not investigated in the
publication. It is possible that it is very useful in vitro but the siRNA are susceptible to
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degradation by nucleases in vivo before they reach the target cells or tissue. To avoid the
possible interaction between the siRNA and RNases, conjugating cationic polymer to
DSPE-PEG can be carried out. There are some commercially available cationic polymers
like PLL, PEI, poly(arginine), etc. Among them, PEI is commercially available and it has
been widely studied for nucleic acid delivery. It is known that it can deliver pDNA and
siRNA and induces endosomal escape. Researchers used PEI to disperse CNT [390] and
therefore, PEI alone can be used instead of using DSPE-PEG as the component to
disperse CNT. However, PEI alone is not efficient to deliver siRNA, modification is
necessary to mediate higher gene silencing. These two different approaches of polymer
modification for CNT dispersion for siRNA delivery in various applications constitute
the following chapters of the thesis. They will be divided into three chapters and the
rationale of the experimental design is given as follow:
In chapter 2, the work focused on utilizing DSPE-PEG for CNT dispersion. DSPE-PEG
was connected to PEI and the resulting polymer was used to disperse CNT. This
approach is more conservative because the DSPE is able to stably disperse CNT. It is a
proof of concept experiment for using PEI to disperse CNT non covalently for siRNA
delivery. Optimal ratios between PEI to PEG was determined at the same time.
In chapter 3, modified PEI was used for CNT dispersion. Previously, succinic acid
modified PEI (PEI-SA) was shown to mediate transfection as well as reducing the
toxicity. However, if the degree of succination is higher than 20%, it cannot mediate gene
silencing. It is because the PEI-SA cannot form a stable complex with siRNA. In
considering that CNT might reduce PEI binding to siRNA, a lower percentage of
succination is more desirable than over functionalization of the PEI. This CNT was
examined for topical siRNA delivery because it has been reported that CNT can mediate
enhanced transdermal drug delivery. Braf is usually mutated and activated in human
melanoma which is believed to be one of the most important genetic aberration in cancer.
A mouse cutaneous melanoma model was used for verifying the transdermal siRNA
delivery as well as therapeutic efficacy of PEI-SA/CNT with Braf siRNA for reducing
tumor progression.
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In chapter 4, the PEI-SA was further modified for CNT dispersion and for tumor-targeted
delivery. PEI and CNT offer no steric stabilization to the CNT/siRNA complex. The
positively charged CNT is very likely to aggregate in the media of negatively charged
serum and cleared by the RES during systematic delivery. PEG was conjugated to PEISA for increasing the colloidal stability of the CNT/siRNA complex. PEG was also
attached to a targeting ligand to the other end of the PEG to enhance the target
specificity. Folic acid was chosen as the targeting ligand because folate receptors are
overexpressed in various cancers. It is known that mTOR is associated with S6K, which
is a gene responsible for cell proliferation. A mouse cutaneous melanoma model was
used for verifying the systematic siRNA delivery as well as therapeutic efficacy of the
folic acid conjugated CNT with mTOR siRNA for reducing tumor progression.
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Chapter 2

2

DSPE-PEG-PEI Non-covalently Functionalized SingleWalled Carbon Nanotubes for siRNA Delivery in vitro
and in vivo
2.1

Summary

Small interfering RNA (siRNA) can specifically down regulate the expression of a
specific gene. It has been shown that modified carbon nanotubes (CNT) protect siRNA
and facilitate its entry into cells, however, easy and efficient functionalization of CNT is
more desirable. Non-covalent functionalization of CNT can be easily carried out and it
has been shown that this approach can be used to deliver siRNA effectively.
Single walled carbon nanotubes (SWCNT) were functionalized by non-covalent
association with a lipopolymer DSPE-PEG. Three different ratios of polyethylenimine
(PEI) to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene
glycol)-2000] (DSPE-PEG) were synthesized and the products were used to disperse
CNT to form DSPE-PEG-PEI/CNT (DGI/C). DGI/C was used for siRNA delivery in
vitro and in vivo.
Three DGI as well as DGI/C were characterized. The structural, biophysical, and
biological properties of DGI/C and their complexes formed with siRNA were
investigated. The cytotoxicities of the three DGI/C were low, while gene silencing with
DGI/C/siRNA complexes was demonstrated in vitro with B16-F10 cells. In addition, we
found significant uptake of siRNA as well as gene silencing in liver by intravenous
administration.
A novel non-covalent functionalization of CNT was developed, which efficiently
delivered siRNA in vitro and in vivo. The new delivery method has provided a new
possibility for siRNA delivery, which could provide insight for the development of noncovalently functionalized CNT for siRNA therapy.
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2.2

Introduction

CNT have been used for gene delivery [1-11] and it has been reported that CNT can gain
into cells as “nano-needles” by a diffusion-like mechanism [12-15]. The type and
dimensions of CNT and the way in which CNT are functionalized determine the
mechanism of cellular entry [16, 17]. However, pristine CNT (p-CNT) are not soluble in
most solvent and so various modifications or functionalizations have been performed to
increase the solubility of CNT in common solvents [18]. CNT can be functionalized
covalently and non-covalently for higher solubility [19, 20]. Despite the fact that CNT
can be functionalized such that they can gain into cells effectively, they can only carry
certain drugs or genes effectively. CNT can bind to single strand DNA [21], but the
choice of sequence is limited as the binding is dominated by the interaction of
hydrophobic bases of DNA and hydrophobic surfaces of CNT. In order to use CNT for
drug or gene delivery, they must be functionalized specifically for the desired application.
siRNA is a powerful tool for research and it is an attractive method to treating disease,
specifically those with known targets However, the application in the clinic is still
limited, largely due to the difficulty in delivery [22-25]. It has been reported that siRNA
can be covalently attached to CNT but this approach limits the siRNA carrying capacity.
Also, siRNA must be modified before it is covalently attached to the CNT, which might
increase the complexity of manufacture. Non-covalent binding of siRNA to CNT is
preferable and stabilization of siRNA with cationic charge is a simple way for CNT to
carry a greater amount of siRNA. Previously, it has been reported that CNT can be
dispersed with DSPE-PEG non-covalently by the virtue of the hydrophobic lipid tail of
DSPE [10, 26, 27]. PEI is a cationic polymer that has been used extensively for nucleic
acid delivery. It can condense siRNA and facilitate endosomal escape [28]. It has been
shown that CNT covalently conjugated with PEI can increase transfection efficiency [2].
In this study, to combine the advantageous transfection properties of PEI and the
properties of DSPE-PEG which enable non-covalent functionalization and dispersion of
CNT. DSPE-PEG-PEI (DGI) was prepared at different ratios of DSPE-PEG to PEI. DGI
was used to non-covalently functionalize CNT. The in vitro siRNA delivery capacities
and cytotoxicity were determined.
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2.3

Materials and Methods

2.3.1 Chemicals
Purified single-walled carbon nanotubes were purchased from Nano-C (Batch PT111260, MA, USA). Polyethylenmine (PEI, Mw 15476, Mn 7893), N-(3Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC), and NHydroxysuccinimide (NHS) were purchased from Sigma Aldrich (St. Louis, MO). 1,2distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000]
(ammonium salt) (DSPE-PEG-COOH) was purchased from Avanti polar lipids, Inc.
(Alabaster, AL). Dimethyl sulfoxide (DMSO) was purchased from Caledon Laboratory
Chemicals, Inc. (Georgetown, Ontario, CA).

2.3.2 siRNAs
Double-stranded siRNAs Silencer® Cy™3 Labeled GAPDH siRNA (siGAPDH) was
obtained from Invitrogen (Burlington, ON, Canada). Luciferase GL2 Duplex was used as
scramble siRNA (siScramble) which was obtained from Thermo Scientific (Ottawa, ON,
Canada).

2.3.3 Nuclear Magnetic Resonance (1H-NMR)
Polymer was dissolved in D2O (99%, Sigma) and was transferred to NMR tube. 1H
nuclear magnetic resonance (NMR) spectra were obtained with INOVA 600 spectrometer
(Agilent, Santa Clara, CA) (600MHz). The spectra were recorded at room temperature
and the D2O peak (4.7 ppm) was used as reference.

2.3.4 Synthesis of 1,2-distearoyl-sn-glycero-3-phosphoethanolamineN-poly(ethylene glycol)-poly(ethylenimine) (DGI)
For DGI 5 and 9, 200 µL (1.75 µmol) of DSPE-PEG-COOH (2.5 mg/mL in chloroform)
was added to a round bottom flask and it was dried with compressed air. Then 5 mL
DMF and 10 mg (52 µmol) of EDC was added. The mixture was stirred for 15 minutes
and then desired amount of PEI solution (23 mg, 2.3 µmol for DGI 5; and 42 mg 4.2
µmol for DGI 9) in MES buffer (0.1 M, pH 5.5) was added. The reaction was allowed to
proceed overnight and then the reaction mixture was dialyzed overnight using a 50 kDa
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molecular weight cut-off (MWCO) regenerated cellulose membrane (Spectrum
Laboratories, Rancho Domingo, USA) against deionized water for 48 hours. The product
was then lyophilized for 2 days. For DGI 18, half the amount (2.5 mg; 0.9 µmol) but the
same procedure of DSPE-PEG-COOH was added to the round bottom flask. Then 5 mL
DMF, 27.0 mg (26.6 µmol) of EDC and 2.80 mg (24.3 µmol) of NHS was added. The
mixture was stirred for 15 minutes and then 19.3 mg (1.93 µmol) of PEI solution was
added. The reaction was allowed to proceed overnight and then the reaction mixture was
dialyzed overnight using a 50 kDa MWCO regenerated cellulose against deionized water
for 48 hours. The product was then lyophilized for 2 days and a white wax like solid was
recovered (27.2 mg; 96% for DGI 5; 52.8 mg; 111% for DGI 9, 26.1 mg; 26.1 mg; 118%
for DGI 18). The 1H-NMR (D2O, 600MHz) for DGI 5: δ 0.90 (m, 6H, -CH3 in stearoyl
tail), δ 1.13-1.30 (m, 21H, -CH2- in stearoyl tail), δ 2.43-3.50 (m, 914H, -NRCH2CH2- in
PEI), δ 3.68 (s, 180H, -OCH2CH2- in PEG); DGI 9: δ 0.91 (m, 8H, -CH3 in stearoyl tail),

δ 1.18-1.30 (m, 26H, -CH2- in stearoyl tail), δ 2.50-3.50 (m, 1634H, -NRCH2CH2- in
PEI), δ 3.68 (s, 180H, -OCH2CH2- in PEG); DGI 18: δ 0.91 (m, 20H, -CH3 in stearoyl
tail), δ 1.25-1.30 (m, 29H, -CH2- in stearoyl tail), δ 2.40-3.50 (m, 3150H, -NRCH2CH2in PEI), δ 3.68 (s, 180H, -OCH2CH2- in PEG). The integral of the methyl group and
methylene group of stearoyl are inaccurate in these 1H-NMR because D2O cannot
disperse the lipid tail well. SEC: DGI 5: Mn = 13440, Mw = 21904, PDI = 1.63; DGI 9:
Mn = 13245, Mw = 21256, PDI = 1.60; DGI 18: Mn = 14645, Mw = 24249, PDI = 1.66.

2.3.5 Size Exclusion Chromatography (SEC) of DGI
The liquid chromatography system was equipped with a Waters Separations Module
2695 (Waters, Mississauga, ON), a Refractive Index Detector (Waters 2414) and three
PLaquagel-OH 40 8µm (300x7.5mm) columns (Polymer Laboratories, Waters)
connected in series and to a PLaquagel-OH 8 µm guard column. 0.2 M ammonium
acetate/acetic acid (pH 5.3) was eluted at 1 mL/min at room temperature for 35 min/ run.
Samples were prepared at a concentration of 10 mg/mL in millique water, filtered
through 0.2 µm Supor membrane filters and injected with a 100 µl volume loop. The
calibration curve was obtained from PEO/PEG standards and the molecular weight was
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calculated by Empower 3 software (Waters). The following standard molecular weights
were used: 615, 1010, 3930, 12140, 20000, 31380, 71700, 106500.

2.3.6 Non-covalent Functionalization of SWCNT by DGI
5 mg of DGI was weighted in a tube and 20 mL of deionized water was added to dissolve
the polymer. Then 5 mg of CNT was added into the polymer solution. The solution was
sonicated for 1 hour at 60 degree Celsius. The undissolved CNT were removed by
vacuum filtration with 0.22 µm Nylon filter. Then the unbounded polymer was removed
by Amicon (MWCO 100 kDa). The concentrated DGI/CNT (DGI/C) was lyophilized,
grey solid was recovered, the recovery of DGI/C 5 was 23.8%, DGI/C 9 was 25.0% and
DGI/C 18 was 23.4% which was calculated by the following equation:
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2.3.7 Transmission Electronic Microscope (TEM)
DGI/C was dissolved in water and dropped onto a copper grid. After 20 minutes, the
solution was removed and the grid was dried under air. The sample was analyzed by a
Philips CM 10 Transmission Electron Microscope (Philips, Eindhoven, the Netherlands)
operating at 80 kV with a 40 µm aperture.

2.3.8 Gel Shift Assay
Equal volume of 0.5 µg of siRNA and desired amount of DGI/C were mixed and
incubated for 30 minutes. Then the complexes were undergone electrophoresis at 100 mV
with 1.5% agarose gel and EtBr in TAE buffer. After 20 minutes, the gel was removed,
visualized and the picture was recorded with FluroChem M (Protein simple, Santa Clara,
CA).

2.3.9 Zeta Potential
DGI/C/siRNA complexes was made by mixing equal volume of siScramble (5 µg) and
desired amount of DGI/C, then the solution was incubated for 30 minutes. The solution
was then transferred to a disposable capillary cell and was analyzed with Malvern
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Zetasizer Nano ZS (Malvern, Worcestershire, UK). He-Ne laser (633nm) with an energy
output of 10 mW with automatic laser attenuation was used for measurements. The mean
and standard derivation of zeta potentials were calculated by 2 measurements of the
average of 10 runs using automatic algorithm.

2.3.10

In vitro Gene Silencing in B16-F10

B16-F10 cells (ATCC, Manassas, VA) were seeded in a 12-well plate with density of
1.2x105 cells/well in 1 mL culture media 24 hours before transfection. DGI/C/siRNA
complexes were made by mixing equal volume of siRNA and 5 times of DGI/C (w/w),
the solution was incubated for 30 minutes. DGI/C/siRNA solution was then added to
serum containing media to have a final concentration of 2 µg/mL of siRNA.
Lipofectamine 2000 (Invitrogen) was used as positive control according to
manufacturer’s protocol. 24 hours after transfection, Trizol method (Life technologies)
was used for RNA isolation and cDNA were synthesized. The mRNA expressions of
GAPDH of samples were quantified with quantitative real time polymerases chain
reaction (qRT-PCR) using rRNA expression of 18S as control. The GAPDH and 18S
primers and the qRT-PCR TaqMan® Assays buffer were obtained from Life
Technologies Inc. (Burlington, ON) and the reactions were done in duplicate with
Stratagene MX 3005p QRT-PCR systems (Mississauga, ON). The reaction condition was
10 min at 95oC, then 40 cycles on 30 s at 95oC, 1 min at 58oC and 1 min at 72oC.

2.3.11

Cytotoxicity in B16-F10

24 hours before transfection, B16-F10 cells were seeded in a 24-well plate with density
of 5x104 cells/well in 500 µL culture media. The media were replaced with culture media
with desired amount of DGI/C. The cells were then returned to incubation for 24 hours.
Media were collected and the cells were typsinized, collected and re-suspended in PBS
with 2% FBS and 5 µg/mL 7AAD. The cells were then analyzed with flow cytometry.
Percentage of cell death was calculated by the 7AAD positive cells in the treated cells
minus the 7AAD positive cells in the untreated cells which were considered as the
background cell death.
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2.3.12

In vivo siRNA Delivery and Gene Silencing

6-8 weeks CD-1 mice (Charles River, Canada) were injected with 200 µg of Cy-3
labelled siGAPDH or siScramble with 200 µg of DGI/C 9 by tail vein and untreated mice
were used as negative control. 24 hours after injection, the mice were sacrificed and the
organs were taken and frozen in -80 oC in OCT or in a tube for later use. Crycosectioning
was done on the organs and they were observed under fluorescence microscope
(Olympus BX51, Olympus Canada Inc., ON, Canada). RNA was isolated with Trizol
method. cDNA was synthesized and qRT-PCR was used to quantify the mRNA
expression of GAPDH of the samples were analyzed and β-Actin was used as internal
control. The reaction condition was 10 min at 95oC, followed by 40 cycles with 30 s at
95oC, 1 min at 62oC and 1 min at 72oC. The primers for GAPDH and β-Actin were:
GAPDH: 5’-GGGGTGAGGCCGGTGCTGAGTAT-3’ (forward), 5’CATTGGGGTAGGAACACGGAAGG-3’ (reverse).

β-Actin, 5’-AGGGAAATCGTGCGTGACATCAAA-3’ (forward) and 5’ACTCATCGTACTCCTGCTTGCTGA-3’ (reverse).
All animals were housed under pathogen-free conditions. All experiments were done in
accordance to the Guide for the Care and Use on Animals Committee Guidelines. The
animal protocol was approved by the Animal Use Subcommittee (AUS) at Western
University.

2.4

Result

2.4.1 Synthesis and Characterization of DGI and DGI/C
DGI was synthesized by activating the carboxyl group in DSPE-PEG-COOH to react
with the amine of PEI (Fig. 2.1). The polymers were characterized with 1H-NMR and
SEC. 1H-NMR (Fig. 2.2) showed that the peak of PEI (2.5-3.0 ppm) and the peak of PEG
(3.68 ppm). The amide peak of PEI (3.0-3.5 ppm) confirmed the successful conjugation
of PEI to DSPE-PEG. There different ratios of PEI to DSPE-PEG were synthesized and
the ratios were calculated by the follow equation:
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The calculated molecular weight by SEC of DGI 5, DGI 9 and DGI 18 are very similar
which is ranging from 13 kDa to 15 kDa for number averaged molecular weight (Mn) and
21 kDa to 24 kDa for weight averaged molecular weight (Mw). Unreacted PEI or DSPEPEG was not observed.
The details were summarized in (Table 2.1).

Figure 2.1 Scheme of DGI synthesis
Reaction scheme of DGI. DSPE-PEG-COOH was activated with EDC and then PEI was
added for the conjugation. DGI was isolated by dialysis followed by lyophilization.
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Figure 2.2 1H-NMR of DGI
1

H-NMR of DGI. DGI 5 from the top, DGI 9 in the middle and DGI 18 at the bottom.

The polymers were dissolved in D2O and the acquisition delay was 5 second.
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Figure 2.3 SEC of DGI
SEC of PEI and three DGI. PEI on the top, followed by DGI 5, DGI 9 and DGI 18. The
bottommost figure is the overlay of all chromatograms. The polymers were eluted by a
0.2 M acetic acid/ammonium acetate (pH 5.3) buffer system with PL aquagel-OH column
and were analyzed by RID.

PEI:PEG ratio PEI:PEG ratio

Mn

Mw

PDI
(Mn/Mw)

(feed)

(1H-NMR)

DGI 5

6.6:1

5.0:1

13440 21904

1.63

DGI 9

12.1:1

8.9:1

13245 21256

1.60

DGI 18a

11.1:1

17.1:1

14645 24249

1.66

Table 2.1 Composition of DSPE-PEG-PEI in weight ratio calculated by 1H-NMR
and molecular weight by SEC
a

DGI 18 was made by EDC/NHS coupling.
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Non-covalent
covalent functionalization is an effective and simple way to obtain water soluble
CNT.. In order to obtain a water soluble CNT which is able to carry siRNA by
electrostatic interaction, DGI functionalized CNT (DGI/C) was made with reference to
Liu’s method [10].. TEM (Fig. 22.4)) showed that DGI/C is singly dispersed and the length
is around 200-1000 nm. The siRNA binding capacity of DGI/C was demonstrated by gel
shift assay. The free siRNA migrates along the gel while the migration of siRNA bound
to DGI/C would be slowed down or totally stopped. Also, the siRNA cannot bind to
ethidium bromide effective
effectively and the fluorescence intensity of the siRNA would be
reduced.. The result showed that for DGI/C 5, the amount of DGI/C required to of siRNA
is 1:1 (w/w) while DGI/C 9 and 18 are at 1:1 (Fig. 2.5).

Figure 2.4 TEM of DSPE
DSPE-PEG-PEI/CNT (DGI/C)
TEM micrograph of DGI/C. Minimum amount of DGI/C solution was added to the
copper grid and was air-dried.
dried. Then the DGI/C was observed with TEM. The length of
the SWCNT was found to be around 200-1000 nm.
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Figure 2.5 Gel shift assay of DGI/C/siRNA
DGI/C/siScramble complexes are made by mixing equal volume of DGI/C and
siScramble. DGI/C was diluted to various concentrations while siScramble concentration
is fixed. The complexes were incubated for 30 minutes at room temperature and the
samples were loaded
aded into agarose gel in TAE buffer (1.5%, w/v) with EtBr. The
complexes were underwent electrophoresis for 30 minutes. Then the gel was taken out for
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illumination under UV. The weight ratio of DGI/C 5 and DGI/C 9 inhibit the siRNA
migration were at ratio 1:1 and DGI/C 18 inhibit the siRNA migration at ratio 2:1.

The stabilities of DGI/C and siRNA complexes were studied by determining the zeta
potential. Electrostatic repulsion of the complexes maintains the stability of the
complexes and thus, the higher magnitude of the zeta potential, the more stable the
complex is. The result (Fig. 2.6) showed that the DGI/C/siRNA complexes have a
positive zeta potential and they are high such that it is an indicator of good colloidal
stability. Interestingly, the zeta potentials are similar for different CNT to siRNA ratios
which were ranged from 47-42 mV for DGI/C 5, 53-48 mV for DGI/C 9 and 37-33 mV
for DGI/C 18. All of the zeta potential is positive because of the incorporation of PEI to
the CNT surface.

Zeta Potentail (mV)
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Figure 2.6 Zeta potential of DGI/C/siRNA
DGI/C/siScramble complexes were prepared using the same method as in gel shift assay.
The sample was then diluted to 1 mL in deionized water and then transferred to a
disposable cell. The experiment was done with 10 runs with duplicate and the error bar is
standard deviation. Four CNT : siRNA ratio (w/w) were tested.
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2.4.2 In vitro Transfection and Cytotoxicity of DGI/C on B16-F10
It has been showed that PEI conjugated CNT could increase the transfection efficiency of
PEI. To reveal the siRNA delivering capacities of three different DGI/C, we set out to
test the gene silencing in B16-F10 and GADPH was used as the target gene in a 24 hour
period. For DGI/C 5, the gene silencing was 75%, the gene silencing of DGI/C 9 was
80% and DGI/C 18 was 60% compared to untreated cells (Fig. 2.7).
To investigate the cytotoxicity of DGI/C, various amount of DGI/C were used to treat
B16-F10 cells for 24 hours and the dead cells were stained with 7AAD. All of the DGI/C
has low cytotoxicity up to 5 µg/mL. DGI/C 9 has a negligible cytotoxicity up to 10
µg/mL. The percentage of cell death was 46% when the concentration increased to 20
µg/mL and continued to increase to 70% for 40 µg/mL. The cytotoxicities of DGI/C 5
and DGI/C 18 are similar. The cell death is around 10% at a concentration of 10 µg/mL
and the cell death increased gradually from 30% to 70% for 20 µg/mL to 40 µg/mL. No
significant difference between all DGI/C (Fig. 2.8)
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Figure 2.7 In vitro gene silencing by DGI/C in B16
B16-F10 cells were transfected with DGI/C and siGAPDH or scramble siRNA. 24 hours
after transfection, the RNA was isolated with Trizol method and cDNA was synthesized.
The gene expression was done by quantitative RT-PCR. Transfections were done in
serum containing media. n=3, Error bar=SD. Asterisk indicated p<0.05 by student’s ttests.
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Figure 2.8 Cytotoxicity of DGI/C in B16-F10
B16-F10 cells were treated with various amount of DGI/C in serum containing media. 24
hours after treatment, the cells were typsinized and collected for 7AAD staining followed
by flow cytometry analysis. Percentage of cell death was calculated by the 7AAD
positive cells in the treated cells minus the 7AAD positive cells in the untreated cells.
n=4, Error bar=SD

2.4.3 In vivo siRNA Delivery and Gene Silencing of DGI/C
DGI/C 5 has the best gene silencing capacity for in vitro experiment. To reveal the
potential of using DGI/C 5 for in vivo siRNA delivery, DGI/C 5 and Cy-3 labelled siRNA
was injected intravenously into CD-1 mice. Fluorescence of siRNA was found mostly in
liver and spleen (Fig. 2.9). There were also fluorescence found in lung and kidney. qRTPCR result showed that gene down-regulation in liver was over 80%. No gene downregulation was observed for other organs (Fig. 2.10).
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Figure 2.9 In vivo siRNA distribution in mice by intravenous injection
DGI/C and siGAPDH was injected into CD
CD-1
1 mouse. 24 hours after the injection. The
mice were sacrificed and the organs were taken out for cryosectioning. The samples were
then observed under fluorescence microscope and representative picture was shown.
Untreated mice were used as negative control.
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Figure 2.10 In vivo gene silencing in five major organs
DGI/C and siGAPDH or siScramble were injected into CD-1 mice, mice were sacrificed
24 hours after injection. Organs heart (a), kidney (b), liver (c), lung (d) and spleen (e)
were homogenized and the RNA was isolated with Trizol method and qRT-PCR was
used to quantify the mRNA expression. n=2 to 4, error bar=SD.

2.5

Discussion

Novel non-covalently functionalized SWCNT were developed for siRNA delivery in
vitro and in vivo. CNT have been used for siRNA delivery [5, 9]. However, covalent
functionalization like acid oxidation might damage the CNT structure [30]. On the
contrary, non-covalent method is relatively easier to be carried out, also, the integrity of
CNT can be preserved.
One of the most efficient methods for non-covalent functionalization is using surfactants
[31]. By the virtue of hydrophobic interaction of the aliphatic tail of the surfactants and
the surface of carbon nanotubes, they can be dispersed in water for further application.
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DSPE-PEG is one of the most promising non-covalent CNT functionalization. It has been
used for siRNA delivery and it would induce significant gene down-regulation [10, 26,
27]. However, the siRNA was covalently attached to the lipid and therefore, the release
of siRNA would be inefficient unless disulphide or other kinds of triggered release was
used for siRNA detachment. Also, the amount of the siRNA has to be determined after
non-covalent dispersion of CNT which makes its application complicated. Furthermore,
siRNA has to be modified for attaching to the lipid which would increase the cost of
siRNA. Therefore, an effective siRNA loading and unloading, with an easy to manipulate
siRNA loading amount and universal siRNA attachment/complexation method is more
desirable. Electrostatic complexation is an effective way to complex any nucleic acid
which is anionic. Also, the release of siRNA can be induced by the interaction of mRNA
or anionic protein in the cells. Furthermore, once the ratios of cationic species and siRNA
were determined such that there is no free siRNA in the complexes, the amount of siRNA
added would be the amount of siRNA in the complexes. Therefore, we set out to use
DSPE-PEG to connect to a polycation such that it can condense and deliver siRNA
effectively.
DSPE-PEG was conjugated to poly-L-lysine to form DSPE-PEG-PLL (DGL) and it was
used to form DSPE-PEG-PLL/CNT (DGL/C) for siRNA delivery (Appendix iii).
However, DGL/C cannot deliver siRNA effectively. This indicates that the DGL/C gains
into cell via endocytotic mechanism. If the CNT can gain entry into cells by diffusion like
mechanism, localization of CNT into cells should be observed. We set out to use another
polycation which could deliver siRNA better than PLL because it could enhance
endosomal escape.
PEI is a polycation and it is effective in delivering pDNA [32]. However, unmodified PEI
is inefficient in delivering siRNA [33, 34]. The covalent attachment of DSPE-PEG to PEI
would enhance the delivery but the degree of modification has to be optimized.
Therefore, we set out to conjugate DSPE-PEG to PEI (Fig. 1). It is interesting that the
yield of the reaction is higher than 100%. It is mostly because PEI is a hygroscopic
polymer and the water removal is still incomplete after 2 days lyophilization. 1H-NMR
showed the successful conjugation of DSPE-PEG to PEI. The chemical shift of the

80
ethylene peaks near to amide (δ 3.12-3.44) confirmed the conjugation. Three different
ratios of PEI to DSPE-PEG 18, 9 and 5 were synthesized and ratios of PEI to DSPE-PEG
were calculated based on the integral of the proton of PEI to PEG. The integral of the
stearoyl tail of three DGI are inaccurate due to the hydrophobicity of the aliphatic chain.
A more accurate integral could be obtained if it was dissolved in a more soluble solvent.
However, the methanol peak overlapped with the PEI peak and it is impossible to
integrate and compare the amount of PEI and PEG. SEC was also used to determine the
molecular weight of the polymer (table 2.1). Interestingly, the molecular weights
determined from SEC are not consistent with the proton NMR result. It is highly possible
that due to the hydrophobic nature of the lipid, the elution time is affected because of the
hydrophobic interaction between the polymer and stationary phrase and thus, the
calculated molecular weights do not reflect the actual molecular weight of the polymer
which was determined by the elution time of the polymer. Also, the calibration standard
is PEG which is not a polycation. It is well-known that polycationic polymers would
interact with the stationary phase. The hydrophobic tail of DSPE future complicated the
interaction between the polymer and the column. However, a more accurate method is
not available and conventional mass characterization technique is not useful. Most of the
characterizations of PEI by mass spectrometric method were done with low molecular
weight PEI (2000 Da) [35, 36], whereas higher molecular weight PEI were usually
analyzed by viscometric [37] or chromatographic method [38-40] with static light
scattering due to the polycationic nature of PEI.
A 50k MWCO dialysis membrane was used instead of lower MWCO, it is because the
hydrophobicity of the stearoyl tail would prevent DSEP-PEG conjugated polymer to
diffuse out of the dialysis membrane. As determined by the SEC, only one component
was eluted out. An interesting observation is that the polydispersity of the polymers are
similar to each other (~1.6) but they are smaller than the original PEI (which is 2.5
according to the manufacturer). It is highly possible that the lower molecular weight PEI
and non-conjugated PEI were removed by dialysis and thus the molecular weight was
narrowed down. After the dispersion of DGI to CNT and forming DGI/C, we observed
the DGI/C under TEM. TEM showed that DGI/C has a length of 200-1000 nm which is
shorter than with the claim of the manufacturer (800 nm to 1000 nm). Therefore, the
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CNT were shortened by this method. This finding is reasonable as reported previously,
sonicated CNT have a shorter length [41].
Next, we tested the capacity of DGI/C to condense siRNA electrostatically. Gel shift
assay was used to assess the siRNA binding capacity of DGI/C. The free siRNA migrates
along the gel while the migration of siRNA bound to DGI/C would be slowed down or
totally inhibited. In addition, the siRNA cannot bind to ethidium bromide effectively and
the fluorescence intensity of the siRNA with ethidium bromide would be reduced. The
result showed that for DGI/C 5 and DGI/C 9, the amount of DGI/C required to inhibit
migration of siRNA is 1:1 (w/w) while DGI/C 18 is at 2:1. It is counter-intuitive because
there is more PEI content and which should bind more siRNA. However, as demonstrated
by the other researchers [42], the binding of siRNA to PEI is weaker but modified PEI
can facilitate the binding of siRNA to PEI. Oskuee et al. reported the same trend in gel
shift assay [43]. Therefore, the relatively low degree modification of DGI/C 18 has worse
siRNA binding capacity compared to DGI/C 9 and DGI/C 5. Colloid stability of the
DGI/C and siRNA complexes are important for siRNA delivery, and therefore, zeta
potentials of DGI/C/siRNA complexes were determined. It is interesting that the zeta
potential of the DGI/C complexes are similar for all the tested ratios. There is a lack of
obvious trend even if there is increases of CNT to siRNA ratio, the zeta potential of the
DGI/C complexes are similar for all the tested ratios. They have zeta potentials around 40
mV which can be considered as stable because the charge repulsion between complexes
inhibits the chance of the complexes to aggregate.
To reveal the siRNA delivering capacities of three DGI/C, we set out to test the gene
silencing in B16-F10 cells. All of the DGI/C/siGAPDH is able to induce gene silencing.
The gene silencing capacity of DGI/C 9 is the best among all compared to the siScramble
control as well as to untreated cells. DGI/C 18 is less effective in inducing gene silencing
which is believed to be the inefficient protection of siRNA in serum containing media.
When the weight ratio of PEI and PEG was reduced to 9:1, the siRNA could be protected
more effectively and DGI/C 5 was showed to have similar siRNA protection efficiency as
DGI/C 9. Another possible explanation is that the zeta potential of DGI/C is the highest
whereas DGI/C 18 is the lowest. For in vitro cell transfection, it has been reported that
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the zeta potential plays an important role in the transfection [44]. The cellular uptake of
DGI/C 9 was determined by flow cytometry (Appendix iv). The result showed that the
cellular entry mechanism is energy dependent. It is possible that after the CNT was
modified by PEI, it gains entry into the cells by endocytotic pathway as reported by Liu
et al [2]. This implies that the trend of siRNA delivery of DGI/C is very similar to
modified PEI.
The cytotoxicity of DGI/C 5 and DGI/C 18 are very similar. The cytotoxicity of DGI/C 9
is low (below 20 ug/mL). The PEI content of DGI/C 18 is the highest and it should be the
most toxic if the toxicity is induced mostly by PEI. Therefore, the toxicity of DGI/C is
not only related to PEI. It is also possible that the cytotoxicity is related to the zeta
potential.
Lastly, we tested the in vivo siRNA delivering capacity of DGI/C 9 with Cy3-labelled
siGAPDH. It was carried out previously in our lab, highest fluorescence can be observed
2 to 4 hours after tail vein injection of liposomes. Most of the red fluorescence was found
in liver and spleen 4 hours after injection. It is not surprising because the
reticuloendothelial system (RES) usually take up most of the particles delivered into the
body intravenously. 24 hours was chosen for gene silencing detection in mRNA level
[45]. Gene down regulation by siRNA was found in the liver, the organ which exhibited
the most fluorescence. No gene down-regulation was found in other organs. The GAPDH
mRNA of heart of the mice injected with siScramble was found to be overexpressed
compared to mice injected with siGAPDH, the siRNA or DGI/C may stimulate the
expression of GAPDH in heart. This result inferred that localization of siRNA in the
organs do not necessary lead to gene silencing. It is possible that the DGI/C/siRNA
cannot gain into some tissue effectively, or the siRNA was degraded in the endosome or
lysosome. As a result, gene silencing cannot be observed in spleen or kidney. Also,
DGI/C may interact with some cellular components and affect the gene expression of
some organs.
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2.6

Conclusion

A novel and efficient non-covalently functionalized CNT for siRNA delivery was
developed. The polymers as well as the CNT were characterized and these CNT
successfully deliver siRNA which mediate significant gene silencing both in vitro and in
vivo. The cytotoxicity of the CNT is low in the concentration for in vitro transfection.
This research provides insight for the further development of CNT-based siRNA delivery
system.
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Chapter 3

3

Topical siRNA Delivery with a Novel Non-covalently
Functionalized Single-Walled Carbon Nanotube for
Melanoma Therapy
3.1

Summary

RNA interference (RNAi) can specifically regulate gene expression, but efficient delivery
of small interfering RNA (siRNA) in vivo is difficult while it has been shown that
modified carbon nanotubes (CNT) protect siRNA, facilitate entry into cells and enhance
transdermal drugs delivery. Single walled carbon nanotubes (SWCNT) were
functionalized non-covalently with succinated polyethyleimine (PEI-SA). In this study,
the water soluble CNT, PEI-SA/CNT (IS/C) were isolated and characterized, the gene
silencing induced by IS/C/siRNA complexes was achieved in vitro in B16-F10 cells. In
vivo delivery was topically applied to shaved mouse skin, as well as topically to a
C57BL/6 mouse melanoma model. We found significant uptake of Cy3-labeled siRNA
specific to Braf (siBraf) and gene silencing in the tumor tissue. Treatment with
IS/C/siBraf resulted in attenuation of tumor growth over a 25-day period. This new
delivery method has provided a new possibility for future siRNA delivery and therapy,
which provides insight for the potential application and development of CNT-based
siRNA delivery.

3.2

Introduction

RNAi through siRNA is powerful tool for research and is an attractive method for
treating disease specifically with a known target. However, the application of this
technology in the clinic is still limited. The bottleneck of the application is the lack of
effective delivery methods for siRNA [1-3]. Topical application of therapeutics is an
attractive strategy for treating cutaneous pathological conditions. This is because of its
non-invasiveness, ease of self-administration, selective targeting to pathological location,
lower dosage and lower systematic toxicity for achieving the therapeutic effect [4, 5].
However, the skin acts as the hurdle for topical delivery. It is well known that the skin
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serves as the first line of defense, preventing most physical and chemical insult as well as
biological invasions. Topical therapeutics is also excluded by the epidermis, while the
stratum corneum (SC) is the stumbling block for transdermal delivery [4, 5]. To
overcome this barrier, various transdermal strategies have been developed [6]. Recently,
CNT have been used for transdermal drug delivery [7-9].
CNT have been explored for various biomedical applications [10-12]. Pristine
CNT (p-CNT) are not soluble in most solvents and therefore various modifications or
functionalizations have been performed to increase the solubility of CNT in common
solvents [13]. CNT have also been functionalized to impart solubility in water [14]. CNT
can be functionalized covalently as well as non-covalently, and these approaches have
been reviewed extensively [15, 16]. CNT have been used for nucleic acid delivery [1719] as well as siRNA delivery [20-27]. It has been reported that CNT can gain entry into
cells effectively and one of the most promising features is that they can act as “nanoneedles” which penetrate cells via a diffusion-like mechanism. The type and dimensions
of CNT as well as the manner in which they are functionalized determine the mechanism
of cellular entry [28, 29].
Despite the fact that CNT can enter cells effectively, they cannot carry siRNA
effectively without modification. Covalent attachment of siRNA to CNT enables siRNA
delivery [27, 30] though siRNA carrying capacity is limited. In addition, siRNA has to be
modified before covalent attachment to the CNT, which might increase complexity for
manufacturing and storage. Non-covalent binding of siRNA to CNT is preferable and
stabilization of siRNA with cationic charge is a simple way to carry a large payload of
siRNA. It has been reported that poly(ethylenimine) (PEI) is a good polymer candidate
for nucleic acid condensation and endosomal escape [31], but it is not very efficient in
delivering siRNA [32]. Modified PEI, however, has been shown to deliver siRNA more
effectively and it exhibits lower toxicity than the unmodified PEI [33]. Various PEI-CNT
were synthesized and were superior to PEI alone for nucleic acid delivery [18, 22] while
CNT can be functionalized non-covalently by PEI. Non-covalent functionalization of
CNT with modified PEI may lead to a highly efficient siRNA delivery vector. Recently,
modified CNT for transdermal drug delivery has been reported [7].
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Cutaneous melanoma is a highly invasive carcinoma which is developed from
melanocytes [34]. Early treatment of the disease is beneficial [35] and topical
applications of siRNA specifically target the gene responsible for proliferation might be
beneficial in reducing tumor progression and metastasis in a mice model [36].
In this study, we developed a method, in which non-covalently functionalized
CNT were designed for topical siRNA delivery. We chose PEI-SA and SWCNT to
combine the siRNA delivering capacity of PEI and the transdermal capacity of CNT. The
synthesized polymers and functionalized CNT were characterized. Overall, the feasibility
of using CNT for transdermal siRNA delivery was tested on a murine melanoma model.

3.3

Materials and Methods

3.3.1 Chemicals
Purified single-walled carbon nanotubes were purchased from Nano-C (Batch PT111260, MA, USA). Polyethylenmine (PEI, Mw 15476, Mn 7893) was purchased from Sigma
Aldrich (St. Louis, MO), and succinic anhydride was purchased from Alfa Aesar (MA,
USA). Dimethyl sulfoxide (DMSO) was purchased from Caledon Laboratory Chemicals,
Inc. (Georgetown, Ontario, CA) and glycerol was purchased from VWR International,
Inc. (Edmonton, Alberta, CA).

3.3.2 siRNAs
Double-stranded siRNAs Silencer® Cy™3 Labeled GAPDH siRNA (siGAPDH) was
obtained from Invitrogen (Burlington, ON, Canada). Luciferase GL2 Duplex used as
scramble siRNA (siScramble) and Braf siRNA (siBraf) were obtained from Thermo
Scientific (Ottawa, ON, Canada). The sequence of siBraf was: GCU UAC UGG AGA
GGA GUU ACA.

3.3.3 Cell Culture
B16-F10 cells were obtained from ATCC (Manassas, VA). Cells were cultured with
DMEM (Gibco, Life technologies, Burlington, ON, Canada) with 10% FBS (Gibco) at
37oC in humidified atmosphere.
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3.3.4 Animals
CD-1 mice and C57BL/6 mice were obtained from Charles River (Canada). All animals
were housed under pathogen-free conditions. All experiments were done in accordance to
the Guide for the Care and Use on Animals Committee Guidelines. The animal protocol
was approved by the Animal Use Subcommittee (AUS) at Western University.

3.3.5 Nuclear Magnetic Resonance (NMR)
Polymer was dissolved in D2O (99%, Sigma) and was transferred to an NMR tube. 1H
nuclear magnetic resonance (NMR) spectra were obtained with INOVA 600 spectrometer
(Agilent, Santa Clara, CA) (600MHz). The spectra were recorded at room temperature
and the D2O peak (4.7 ppm) was used as reference.

3.3.6 Synthesis of Succinated Polyethylenimine (PEI-SA)
PEI-SA was synthesized based on Zintchenko’s method [33]. Briefly, 0.60 g (0.06 mmol)
of PEI was dissolved in 10 mL of water. NaCl (0.25 g) was added and the pH was
adjusted to 5 by the addition of 12 M HCl. 72.2 mg (721 µmol) of succinic anhydride was
then dissolved in 10 mL of DMSO and was added drop-wise into the PEI solution. The
reaction mixture was stirred at room temperature overnight and then was dialyzed using a
15 kDa molecular weight cut-off (MWCO) Spectra regenerated cellulose membrane
(Spectrum Laboratories, Rancho Domingo, USA) against 0.25 M NaCl solution for 4
hours followed by 44 hours with deionized water. The water changed 3 times per day.
The product was then lyophilized and a yellow solid was recovered (0.77g; 114%). 1HNMR (D2O, 600MHz): δ 2.4 (s, 4H of succinic acid), δ 2.77-3.56 (m, 4H of
polyethylenimine). 5.3% of the amine in PEI were succinated. Percentage of succinic
acid modification was calculated by:


?  

1@ AB
? 
 100%
1@ AB
!

3.3.7 Non-covalent Functionalization of SWCNT by PEI-SA
5 mg of PEI-SA was weighed in a tube and 20 mL of deionized water was added to
dissolve the polymer. Then, 5 mg of CNT was added into the polymer solution. The
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solution was sonicated for 1 hour. The undissolved CNT were removed by vacuum
filtration with a 0.22 µm Nylon filter. Then, the unbound polymer was removed by using
an ultra-15 centrifugal filter units (100 kDa MWCO, Amicon, Billerica, MA). The
concentrated PEI-SA/CNT (IS/C) was lyophilized and a black solid was recovered
(28.2%). Percentage of recovery was calculated as follow:




 


C/ 

  


 100%
! D CE

3.3.8 Transmission Electronic Microscope (TEM)
IS/C was dissolved in water and dropped onto a copper grid. After 20 minutes, the
solution was removed and the grid was dried under air. The sample was analyzed by a
Philips CM 10 Transmission Electron Microscope (Philips, Eindhoven, the Netherlands)
operating at 80 kV with a 40 µm aperture.

3.3.9 Gel Shift Assay
Equal volumes containing 0.5 µg of siRNA and the desired amount of IS/C were mixed
and incubated for 30 minutes. The resulting complexes were electrophoresed at 100 mV
using 1.5% agarose gel and EtBr in TAE buffer. After 20 minutes, the gel was removed,
visualized under UV lamp and the picture was taken with an Olympus C8080 digital
camera (Olympus, Center Valley, PA).

3.3.10

Zeta Potential

IS/C/siRNA complexes were prepared by mixing equal volumes containing siScramble (5
µg) and desired amount of IS/C, then the resulting solution was incubated for 30 minutes.
The solution was then transferred to a disposable capillary cell and was analyzed using a
Malvern Zetasizer Nano ZS (Malvern, Worcestershire, UK) with He-Ne laser (633nm).
An energy output of 10 mW with automatic laser attenuation was used for measurements.
The mean and standard derivation of zeta potentials were calculated with average of 10
runs using automatic algorithm.
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3.3.11

In vitro Gene Silencing in B16-F10

B16-F10 cells were seeded in a 12-well plate with density of 1.2x105 cells/well in 1 mL
culture media 24 hours before transfection. IS/C/siRNA complexes were made by mixing
equal volumes of siRNA and 5 times IS/C (w/w), then the solution was incubated for 30
minutes. Then the IS/C/siRNA solution was transferred to serum containing media in cell
culture to have a final concentration of 2 µg/mL of siRNA. 24 hours after transfection,
the RNA was extracted using the Trizol method and cDNA was synthesized. The mRNA
expressions of Braf in the samples were quantified with qRT-PCR in a Stratagene MX
3005p QRT-PCR systems (Mississauga, ON) using β-Actin as a reference. The reaction
condition was 10 min at 95oC, followed by 40 cycles with 30 s at 95oC, 1 min at 62oC
and 1 min at 72oC. The primers for Braf and β-Actin were:
Braf, 5’-CAATTGGCTGGGACACGGACAT-3’ (forward) and 5’TTGACAACGGAAACCCTGGAAAAG-3’ (reverse);
β-Actin, 5’-AGGGAAATCGTGCGTGACATCAAA-3’ (forward) and 5’ACTCATCGTACTCCTGCTTGCTGA-3’ (reverse).

3.3.12

Cytotoxicity in B16-F10

24 hours before transfection, B16-F10 cells were seeded in a 24-well plate with density
of 5x104 cells/well in 500 µL culture media. The media were replaced with culture media
with desired amount of IS/C and PEI. The cells were then returned to incubation for 24
hours. Media were collected and the cells were typsinized, collected and re-suspended in
PSB with 2% FBS and 5 µg/mL 7AAD. The cells were then analyzed with flow
cytometry. Percentage of cell death was calculated by the 7AAD positive cells in the
treated cells minus the 7AAD positive cells in the untreated cells which were considered
as the background cell death.

3.3.13

Proliferation Assay for B16-F10 cells

B16-F10 cells were seeded in a 6-well plate with density of 2.4x105 cells/well in 2 mL
culture media. 1 µg/mL of Braf siRNA was used for silencing B16-F10 cells with 2
µL/µg Lipofectamine 2000 (Invitrogen, Burlington, ON, Canada). 24 hours after
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transfection, the cells were trypsinized and reseeded into a 96 well plate (500 cells per
well). The cells were then incubated for 96 hours and media were removed. 20 mg/mL of
MTT (Calbiochem, Gibbstown, NJ) in serum free media was added and incubated for 3
hours. The media were removed and DMSO was added to dissolve the crystals. The
absorbance at 570 nm was recorded using a Tecan Infinite M1000 PRO (Manndorf,
Switzerland).

3.3.14

Topical siRNA Delivery and in vivo Gene Silencing IS/C

CD-1 mice were anaesthetized and shaved. In the no incubation treatment, 6 µg of Cy3labelled siGAPDH was mixed with glycerol (50% in final solution v/v), DMSO (10% in
final solution v/v) and nuclease free water. The desired amount of IS/C was then mixed
with the siRNA solution and the mixture was applied onto the mice's skin immediately.
For IS/C/siRNA with incubation, equal volumes of Cy3-labelled siGAPDH (6 µg) and
desired amount of IS/C was mixed and incubated for 30 minutes. After the IS/C/siRNA
solutions were mixed with glycerol (50% in final solution v/v), DMSO (10% in final
solution v/v) and nuclease free water before the solution was immediately applied to the
mice's skin. The area of application is around 0.25 cm2 (0.5 cm x 0.5 cm). The mice were
sacrificed 4 hours after the application and the skin was cleaned with water and then
removed for cryosectioning and staining with H&E. The penetration of Cy-3 labeled
siRNA into the skin was observed by fluorescent microscopy.
To determine the efficacy of gene silencing, the same no incubation method was carried
out expect that the mice were sacrificed 24 hours after the application instead of 4 hours.
The skin was used for RNA extraction by Trizol method with the aid of a homogenizer.
cDNA was synthesized and the mRNA levels of GAPDH was quantified by qRT-PCR
using β-Actin as reference. qRT-PCR was carried out using the same procedure described
above and the sequence of the GAPDH primers were: GAPDH: 5’GGGGTGAGGCCGGTGCTGAGTAT-3’ (forward), 5’CATTGGGGTAGGAACACGGAAGG-3’ (reverse).
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3.3.15

Topical siRNA Delivery and Gene Silencing in Tumor in
Melanoma Bearing Mice

Melanoma bearing mice were generated by inoculating 2x105 B16-F10 cells intradermally into C57BL/6. Seven days after tumor inoculation, mice were anesthetized and
IS/C/siRNA without incubation was applied onto the tumor. To test for siRNA
penetration, the tumor was removed twenty four hours after siRNA application and
frozen in OCT for cryosectioning. Images were obtained using a fluorescence microscope
(Olympus BX51, Olympus Canada Inc., ON, Canada)
The same procedure was applied for topical siRNA delivery but the tumor was treated for
48 hours. RNA was isolated using the Trizol method for qRT-PCR and protein was
extracted for western blotting.

3.3.16

Treatment of Melanoma Bearing Mice Using IS/C and Braf
siRNA

Melanoma bearing mice were generated by inoculating 2x105 B16-F10 cells intradermally into C57BL/6. Three days after tumor inoculation, mice were anesthetized and
randomized according to the observed size of the appearance of black pigment. IS/C (12
µg), siRNA (6 µg, siBraf or siScramble), glycerol (50% in final solution v/v), DMSO
(10% in final solution v/v) were mixed without incubation and was applied onto the
tumor every other day. The tumor sizes were measured with caliper. Twenty five days
after tumor inoculation, the mice were sacrificed and tumors were removed. The tumor
weights were measured with a 2-digit electronic balance.

3.3.17

Statistics

Data were expressed as mean± standard error or standard deviation of the mean and the
results were analyzed a by one way ANOVA followed by Dunnett's test as post-test,
student’s t-test or two way ANOVA followed by Bonferroni’s test as post-test. p < 0.05
was considered statistically significant. All the data analysis was performed in GraphPad
Prism.
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3.4

Results

3.4.1 Synthesis and Characterization of PEI-SA and PEI-SA/CNT
(IS/C)
It has been shown that branched PEI is not effective in delivering siRNA due to its strong
complexation with the siRNA. In order to increase the siRNA protection, PEI-SA was
synthesized (Fig. 3.1) [33]. In initial work, both 5% and 10% modification of the amines
was investigated and it was found that 5% amine modification was better for CNT
dispersion. Therefore, subsequent work focused on the preparation and study of this
polymer. We found that the percentage of succination was more consistent if the reaction
was performed overnight instead of for 3 hours. Following removal of unreacted succinic
acid by dialysis, 1H NMR spectroscopy of the product (Fig. 3.2) showed that peaks
corresponding to the methylene protons of PEI (2.7-3.6 ppm) and the proton of succinic
acid were present (2.49 ppm), confirming the successful modification of PEI with
succinic acid.

Figure 3.1 Scheme of synthesis of PEI-SA
Reaction scheme of PEI-SA. PEI was reacted with succinic anhydride overnight to form
polyethylenimine-succinic acid (PEI-SA). PEI-SA was isolated by dialysis followed by
lyophilization.
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5.27
2.5

Figure 3.2 1H-NMR of PEI-SA
1

H-NMR of PEI-SA the polymer was dissolved in D2O and the acquisition delay was 5

second.

Non-covalent functionalization is an effective and simple way to obtain water soluble
CNT [37]. In order to obtain a water soluble CNT which is able to carry siRNA, we
functionalized CNT using PEI-SA (IS/C) [27]. TEM (Fig. 3.3) showed that IS/C was
singly dispersed with a length ranging from 200 nm to 1 µm.
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Figure 3.3 TEM micrograph of IS/C
Minimum amount of IS/C solution was added to the copper grid and was air-dried.
air
The
length
th of the SWCNT ranges from 200 nm to 1 µm.

The siRNA binding capacity of IS/C was demonstrated by gel shift assay. The free
siRNA migrates along the gel while the migration of siRNA bound to IS/C is slowed
down or totally stopped. In addition
addition, the bound siRNA cannot bind to ethidium bromide
effectively and thus the fluorescence intensity of the bound siRNA would be reduced.
The results showed that the amount of IS/C required to neutralize the charge of siRNA is
2:1 (w/w) as unbound siRNA was not observed at this ratio (Fig. 3.4).

Figure 3.4 Gel shift assay of siRNA with IS/C
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IS/C/siScramble complexes are made by mixing equal volume of IS/C and siScramble.
IS/C was diluted to various concentrations while siScramble concentration is fixed. The
complexes were incubated for 30 minutes at room temperature and the samples were
loaded into agarose gel in TAE buffer (1.5%, w/v) with EtBr. The complexes were
subjected to electrophoresis for 30 minutes. Then the gel was taken out for illumination
under UV. The weight ratio of siRNA condensed by IS/C is 2:1.

The stability of IS/C and siRNA complexes was studied using zeta potential
measurements. The higher the magnitude of the zeta potential, the more stable the
complexes would be due to electrostatic repulsion. The result showed that the
IS/C/siRNA complexes have a strongly positive zeta potential, which indicate good
colloidal stability (Fig. 3.5).

Zeta Potential
Zeta Potentail (mV)
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Figure 3.5 Zeta potential of IS/C/siRNA
The sample was dispersed in deionized water. The experiment was done with 10 runs and
the error bar is zeta deviation.
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3.4.2 In vitro Transfection and Cytotoxicity of IS/C on B16-F10
It has been shown that PEI conjugated with CNT could increase the transfection
efficiency of PEI [22, 38]. To reveal the potential of IS/C in siRNA delivery, we
examined the efficacy of gene silencing using siBraf delivered by IS/C in B16-F10 cells.
Compared to untreated cells (Fig 3.6), the Braf expression of cells transfected with IS/C
and siScramble have no significant difference. The cells transfected with IS/C and siBraf
have significant difference between siScramble treated and untreated cells. The
percentage of Braf down regulation was found to be 80% by qRT-PCR. The cytotoxicity
of IS/C was determined in B16-F10 and PEI 10k (Mn) was used as a comparison. IS/C
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has a lower cytotoxicity compared to PEI in the tested concentrations (Fig 3.7).

Figure 3.6 In vitro gene silencing using IS/C
B16-F10 cells were transfected with IS/C and siBraf or scramble siRNA. 24 hours after
transfection, the RNA was isolated with Trizol method and cDNA was synthesized. The
gene expression was done by quantitative RT-PCR. Transfections were done in serum
containing media. Error bar=SD, n=4.
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Figure 3.7 Cytotoxicity of IS/C
B16-F10 cells were treated with various amounts of IS/C and PEI in serum containing
media. 24 hours after treatment, the cells were trypsinized and collected for 7AAD
staining followed by flow cytometry analysis. Percentage of cell death was calculated by
the 7AAD positive cells in the treated cells minus the 7AAD positive cells in the
untreated cells. n=3, Error bar=SD

3.4.3 Cell Proliferation of Braf siRNA treated B16-F10 cells
Next, we examined whether the knockdown of Braf by siRNA affects the cell
proliferation, it is a kinase which could phosphorylate MEK [39], it is a critical molecule
in the MAPK pathway and which leads to tumor growth [40], may influence B16-F10
melanoma cell proliferation. MTT interacts with CNT and therefore it is not a reliable
cytotoxic assay for the cell proliferation [41], we tested cell proliferation of B16-F10
after gene silencing of Braf using Lipofectamine 2000 instead of using IS/C (Fig. 3.8).
Compared to untreated cells and cells transfected with scramble siRNA, siBraf reduced
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the proliferation of B16-F10 cells by almost 60%. Taken together, these data suggest that
IS/C is effective in delivery of siRNA. Induction of Braf gene silencing in B16-F10 cells
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results in inhibition of tumor cell proliferation in vitro.

Figure 3.8 Cell proliferation of B16-F10 by MTT
B16-F10 cells were transfected with siBraf and lipofectamine 2000 and after 24 hours,
cells were trypsinized and 500 cells were seeded into 96 wells plates. The cells were then
incubated for additional 96hr. Then media were replaced with serum free media with
10% MTT and the cells were incubated for 3 more hours. Media were removed and
DMSO was added to wells and the absorbance at 570 nm was recorded. n=6; error
bar=SD (* indicates p<0.05 by two tail student’s t-test)
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3.4.4 Topical siRNA Delivery and Gene Silencing to CD-1 Mice Skin
with IS/C
CNT have been used for transdermal drug delivery. However, they have not been used
for transdermal siRNA delivery. In order to investigate the potential of using IS/C to
deliver siRNA into skin, IS/C and siRNA was topically applied on CD-1 mice. Untreated
mouse skin was used as negative control (Fig. 3.9a) and Cy-3 labeled siRNA was used as
the background control (Fig. 3.9b). Recently developed by our lab, Lipofectamine 2000
with 10% DMSO and 50% glycerol was used as a positive control [42] (Fig. 3.9c) PEISA with 10% DMSO and 50% glycerol was used as a comparison (Fig 3.9d&e).
Fluorescence was observed 4 hours after the application was chosen with reference to
other researchers in topical siRNA delivery [43]. siRNA was not incubated with PEI-SA.
Interestingly, PEI-SA does not enhance the penetration of siRNA into skin regardless of
the ratio tested (2:1 and 5:1). IS/C with different IS/C to siRNA ratios were tested with
10% DMSO and 50% glycerol. IS/C were incubated with siRNA (Fig. 3.9f-h) and no
incubation was used as comparison (Fig. 3.9i-k) for transdermal delivery. For the
incubated IS/C/siRNA, as the ratio of IS/C increases, the siRNA penetration into the skin
reduced. For IS/C without siRNA incubation, 3 of the tested ratios have similar depth of
siRNA penetration into the skin. The result demonstrated that polymer alone cannot
effectively deliver siRNA topically while IS/C is able to deliver siRNA. Therefore, CNT
are crucial to facilitate the transdermal siRNA delivery. The gene silencing of IS/C with
siGAPDH and siScrabmle on skin were also carried out. The result showed around 50%
of GAPDH was down regulated (Fig. 3.10).
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Figure 3.9 Topical siRNA delivery by IS/C in CD
CD-1 mice
The mice were anesthetized and shaved. siRNA was labeled with Cy
Cy-3
3 fluorescence dye,
the siRNA solutions were applied onto the skin. The mice were sacrificed 4 hours after
siRNA solution application. The skin samples were removed and cryosectioned. The
photos
tos were taken with florescence microscope. (a) Untreated skin as negative control;
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(b) siRNA only as Cy-3 labeled siRNA only control; (c) lipofectatmine 2000 (L2K) as
positive control. PEI-SA with a 5:1 (d) and 2:1 (e) ratios were used to compare with the
one without CNT. IS/C with different ratios and with different preparation method were
compared. siRNA and IS/C were incubated for 30 minutes and then mixed with DMSO
and glycerol solution for (f), (g) and (h) (IS/C to siRNA ratio 2:1, 3:1 and 5:1) while
siRNA were mixed with DMSO and glycerol solution. Then IS/C was added to the
solution and immediately applied to the mice skin for (i) (j) and (k) (IS/C to siRNA ratio
2:1, 3:1 and 5:1). 10% DMSO and 50% glycerol was added from (c) to (k) as transdermal
enhancer. Compared to polymer alone, CNT is important for topical siRNA delivery.
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Incubation of IS/C and siRNA reduced the skin penetration of siRNA.

Figure 3.10 Topical gene silencing with IS/C and siGAPDH
The gene silencing on skin was quantified by qRT-PCR. mRNA expression of GAPDH
was normalized with the mRNA expression of β-Actin. n=3, error bar=SEM
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3.4.5 Gene silencing in melanoma using IS/C
To investigate the feasibility of using IS/C to deliver siRNA into melanoma, we
generated a murine melanoma model by inoculating B16-F10 cells into C57BL/6 mice.
After tumors formed, we applied IS/C-siRNA once locally to the tumor-bearing mice.
The siRNA penetration into the tumor was observable (Fig. 3.11).
The qRT-PCR result showed that the gene down regulation for the siBraf was over 70%,
while the siScramble and untreated tumors had no significant difference in Braf
expression (Fig. 3.12). Western blot of the tumor samples also showed similar results
(Fig. 3.13). Taken together, these results suggested that topical application of IS/C with
siBraf is capable of down-regulating Braf in tumors in terms of both RNA level and
protein level.
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Figure 3.11 Topical delivery of siRNA to tumor
Tumor bearing mouse was applied with ISC/Cy3
ISC/Cy3-labeled
labeled siRNA complexes. 24 hours
after the application, the tumor was removed and frozen in OCT. It was cryosectioned
and the photos were taken with fluorescence microscope
microscope. Photo on the left is an untreated
tumor sample while photo on the right is the topically treated tumor. The arrow indicated
the tumorous tissue (large nucleus, reduced cytoplasm)
cytoplasm).
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Figure 3.12 Gene silencing of topically treated tumor with IS/C/siBraf by qRT-PCR
Tumor bearing mice were treated with IS/C/siBraf, 2 days later, the mice were sacrificed
and the tumor samples were removed. The tumor samples were homogenized and the
RNA were isolated by Trizol method for qRT-PCR. n=6; Error bar=SEM (* indicates
p<0.05 by one way ANOVA, followed by Dunnett’s test as posttest)
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Figure 3.13 Gene silencing of topically treated tumor with IS/C/siBraf by western
blot
Tumor bearing mice were treated with IS/C/siRNA, 2 days later, the mice were sacrificed
and the tumor samples were removed. (a) The tumor samples were homogenized and the
protein was isolated withh RIPA buffer for western blot. Representative image was
showed. (b) Quantification of the protein band intensity of the western blot by photoshop.
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3.4.6 Treatment of Melanoma Through Topical siRNA Delivery of
Braf siRNA using IS/C
Braf is an important gene in the MAPK pathway, which is responsible for regulating cell
growth and proliferation. To test the feasibility whether topically knocking down of Braf
may inhibit melanoma progression, we treated melanoma-bearing mice with IS/C and
Braf siRNA. The tumor size is significantly different for the IS/C/siBraf from tumor
treated with IS/C/scrambled siRNA. The tumor growth was inhibited significantly but the
tumors did not regress. There is no significant difference between untreated tumor and
tumor treated with IS/C/scrambled siRNA (Fig. 3.13). A similar trend was observed in
the average tumor weight when the mice were sacrificed on day 25. The final tumor
weight was not significantly different between untreated mice and IS/C/scrambled siRNA
treated mice while the IS/C/siBraf treated tumor was dramatically reduced (Fig. 3.14).
These data imply that IS/C/siBraf is able to reduce the tumor progression by Braf downregulation.
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Figure 3.14 Tumor size of tumor bearing mice topically treated with IS/C/siBraf
3 days after the mice were inoculated with tumor, the mice were topically applied with
IS/C/siRNA solution for every 2 days. The tumor size of mice was estimated by the
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length and width of the tumor by a caliber in nearest 0.5 mm. The sizes were calculated
with π(LxW2)/6. 2-way ANOVA with Bonferroni’s test as post-test showed that
significant difference between the scramble control and the IS/C/siBraf group. Significant
difference of tumor volume begin from 21st day (p<0.05), to 23rd day (p<0.001) and 25th
day (p<0.001). n=6 for untreated mice and siScramble, n=7 for siBraf; error bar=SEM
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Figure 3.15 Tumor weight of tumor bearing mice topically treated with IS/C/siBraf
3 days after the mice were inoculated with tumor, the mice were topically applied with
IS/C/siRNA solution for every 2 days. The tumor weight of mice was removed and
weighted on the day when the mice were sacrificed (Day 25). n=6 for untreated mice and
siScramble, n=7 for siBraf; error bar=SEM (Asterisk indicated p<0.05, samples analyzed
by 1-way ANOVA followed by Dunnett’s test as post-test by comparing with siScramble
group)

3.5

Discussion

Transdermal delivery of therapeutics has many advantages over oral or systematic
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delivery. There are fewer digestive enzymes, the pH is not extreme, and the treatment is
both non-invasive and can be self-administered. If it is a topical pathological condition,
topical delivery is more efficient due to higher bioavailability because of the proximity.
This can also result in lower systematic toxicity. However, the epidermis of skin,
especially the SC, prevents most of the diffusion of exogenous chemicals. Even though
the siRNA passed the SC barrier, it cannot gain entry into the cells effectively because
the cell membrane is another barrier. Both siRNA and cell membranes are anionic and
therefore tend to repel each other [44, 45]. Thus, an efficient transdermal siRNA delivery
vector is required. Transdermal siRNA delivery has been carried out and some success
has been attained [43, 46]. CNT have been shown to enhance transdermal drug delivery
[7, 9].
Cutaneous melanoma is a carcinoma developed on skin, and in human cutaneous
melanoma, Braf is usually overexpressed and mutated which is well-studied that it is
responsible for cell proliferation [47]. Braf inhibitor has been used in clinical trials, but
resistance to it has been observed [48], therefore an alternative approach for Braf
inhibition for treating or reducing the tumor progression is needed. siRNA is a good
candidate because it induces post transcriptional gene silencing which would not
circumvent drug resistance. Braf silencing could be the alternative approach to reduce
tumor progression.
Vertically aligned CNT can act as nano-spear for drug delivery [49] but the safety of
insoluble CNT is an issue because its accumulation and retention can be toxic and induce
undesirable immune responses [50]. Therefore, we functionalized the CNT to make them
water soluble and biocompatible. Our design was to disperse the CNT with a water
soluble polycation PEI to test if the CNT and the siRNA delivering capacity of succinated
PEI are compatible such that a good transdermal siRNA delivery can be achieved.
Novel non-covalently functionalized SWCNT were developed for siRNA delivery in
vitro and topically in vivo. CNT have been used for siRNA delivery [22, 26] as well as
topical drug delivery [7-9], however, they have not been used for topical delivery for
siRNA. The SC is the stumbling block for topical therapeutic agent delivery due to its
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hydrophobic nature. CNT have a high aspect ratio and they are hydrophobic, thus it might
enhance the penetration of macromolecules.
We succinated the amine of PEI to make PEI-SA and interestingly, the yield is higher
than 100%. It is highly possible that PEI is a hygroscopic polymer and water cannot be
totally removed by 2 days lyophilization. PEI-SA was characterized using 1H NMR
spectroscopy and it was found that 5% of the amines were modified with succinic acid.
The CNT were dispersed with PEI-SA by a sonication method and the water soluble CNT
were recovered by removing the insoluble CNT and the unbound polymer by
ultrafiltration. IS/C is singly dispersed CNT with length ranging from 200 nm-1000 nm.
The CNT were shortened by sonication. IS/C condense the siRNA at a ratio of 2:1 (w/w).
Moreover, its complex with siRNA has a stable zeta potential in the tested ratios. It is
important to have a high magnitude of zeta potential so the siRNA is well protected as
well as being stable as water soluble suspension. IS/C successfully delivered siRNA in
vitro into B16-F10 cells and the Braf expression of were reduced by 80%. The
cytotoxicity of IS/C is lower than PEI alone. It is possible that for IS/C, the cytotoxicity is
induced mostly because of the polymer.
The topical delivery of siRNA with IS/C was demonstrated by observing the fluorescence
of Cy-3 labelled siRNA 4 hours after topical siRNA application. The duration was
optimized by a previous study using siRNA with glycerol and DMSO in our lab, the
fluorescence between 1 to 4 hours is similar while the fluorescence attenuated for longer
duration. Interestingly, siRNA cannot penetrate into the skin with PEI-SA alone, while
IS/C is very effective in delivering siRNA into the skin. It is probably due to the size of
CNT such that the siRNA wrapped on top of CNT can effectively enter into the dermis.
Another notable observation is that the IS/C incubated with siRNA has less penetration
compared to IS/C added to siRNA without incubation. Although both of them deliver
siRNA into the skin, no incubation is better than incubated IS/C/siRNA. The reason for
the reduced transdermal capacity after incubation is unknown. It is possible that the IS/C
act as transdermal enhancer or the initial formation of IS/C/siRNA complexes has a
higher transdermal activity. For later experiments, we used a IS/C: siRNA ratio of 2:1
with 10% DMSO and 50% glycerol without incubation. Both DMSO and glycerol act as
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transdermal enhancer, however, DMSO and glycerol alone cannot achieve efficient
siRNA skin penetration. IS/C, on the other hand, can deliver siRNA into the skin and into
the tumor. There is a significant gene down regulation after IS/C/siRNA was applied to
both skin and tumor. It is interesting that the percentage of gene down regulation in
tumors was higher than the skin, which is probably because tumor cells take up the
IS/C/siRNA complexes more actively compared to cells in the dermis.
Topical siRNA delivery into cutaneous melanoma for tumor growth inhibition in a mice
model was previously demonstrated by Tran et al [36]. However, they used sonoporation
for enhanced transdermal activity. We set out to demonstrate the same concept by using
Braf siRNA and carbon nanotubes without sonoporation. It is known that Braf is not
mutated in B16-F10 cells [51], but in humans, the cell proliferation of wild type Braf
plays a role in Craf activation [52]. The cell proliferation experiment also demonstrated
that Braf downregulation in B16-F10 cells reduced the proliferation compared to the
control. A similar trend was observed for the tumor size of the IS/C/siBraf treated mice.
The inhibition was significant compared to the scramble control as well as untreated
tumor. In the observed period (25 days), the tumors of the IS/C/siBraf treated group had
not progressed significantly compared to control groups. As a proof of concept
experiment on utilizing CNT for siRNA delivery, our experimental was designed to
maximize the effect of siRNA topical therapy and to try to exploit the most promising
feature of topical delivery, the ease of administration and a more frequent schedule of
reagent administration. The promising feature of this siRNA delivery system is that the
IS/C could enhance the siRNA delivery without using instruments for skin permeation
enhancement. One possible advancement upon this delivery system could be the
development of a transdermal patch instead of using applied siRNA solution. A
continuous release of drug with the physical protection of the patch could be beneficial
for long lasting gene down regulation, which would also circumvent the trouble of
frequent applications.
Cutaneous melanoma is a highly invasive disease. The patients’ delays as well as
diagnostic delay are important factors for impeding early diagnosis and treatment [53].
To compensate the delay, it would be ideal if there were a topical drug delivery system to
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suppress the growth of melanoma or even induce tumor regression if immediate surgical
removal is not possible. The patients can apply the drug themselves easily and tumor
growth can be slowed down immediately, improving patient the survival. Based on our
animal experiments, this topical siRNA delivery system might be able to carry out the
above mentioned function and provides a possible alternative to current melanoma
treatment. Further experiment on the transdermal behavior in an artificial human skin is
needed for the testing the therapeutic potential of this delivery system. Although in the
clinical settings, most of the early stage melanoma was treated by surgical removal, it
would be beneficial to control the growth of late stage melanoma. The topical application
of siRNA targeting normal Braf is a local delivery and the possible side effect could be
minimal, however, the inhibition of normal Braf would affect the Braf function of healthy
tissue. The possible improvement on the therapy in future experiments to circumvent the
side effect would be using a combination of mutated Braf (V600E for example) and
MEK/ERK silencing [54], Akt3 [36] or mTOR silencing [55] for reducing tumor
progression. Another possibility to utilize this transdermal siRNA delivery system is for
melanoma prevention. The concept was demonstrated by Chung et al. with an inhibitor
[S,S’-1,4-phenylenebis(1,2-ethanediyl)bis-isoselenourea] (PBISe) [56]. Furthermore, this
topical siRNA delivery system can potentially be used for treating skin diseases such as
dermatitis.

3.6

Conclusion

A novel non-covalently functionalized SWCNT with IS/C for topical siRNA delivery
was developed. The polymer for dispersing the CNT and the IS/C were characterized.
The capacity for delivering siRNA in vitro and topically in vivo was demonstrated. The
potential of utilizing this CNT for RNAi therapy was further tested with Braf siRNA on a
melanoma model. Significant tumor progression reduction was observed in a 25 day
interval. Thus, this novel topical siRNA delivery system has a potential to be used as
tumor progression inhibition in a clinical setting.
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Chapter 4

4

Targeted siRNA Delivery with a Folic Acid Conjugated
Single-Walled Carbon Nanotube for Cancer Therapy
4.1

Summary

RNA interference (RNAi) can specifically regulate the gene expression, but efficient and
targeted delivery of small interfering RNA (siRNA) in vivo to pathological cells or tissue
is difficult. It has been shown that modified carbon nanotubes (CNT) protect siRNA and
facilitate its entry into cells. Folate receptor (FR) is overexpressed in cancer and it has a
high binding constant with folic acid.
Single walled carbon nanotubes (SWCNT) were functionalized by non-covalent
association with a folic acid conjugated polyethylenimine (PEI). PEI was modified with
polyethylene glycol (PEG) and succinic acid. This product was used to disperse CNT and
water soluble CNT were isolated for siRNA delivery. In vivo siRNA delivery was done
by intravenous injection to melanoma bearing mice and mTOR siRNA (si-mTOR) was
used to test in vivo gene silencing and anti-cancer therapy since mTOR is usually
overexpressed in cancer.
The polymers as well as the CNT with folic acid (FGIS/C) and without folic acid (GIS/C)
were characterized. The structural, biophysical, and biological properties of FGIS/C and
GIS/C and their complexes formed with siRNA were investigated. We found significant
uptake of siRNA as well as gene silencing in tumor by FGIS/C. Treatment with
FGIS/C/si-mTOR resulted in attenuation of tumor growth in a murine melanoma model.
In conclusion, a novel functionalized targeted CNT was developed for cancer siRNA
delivery, which siRNA was delivered in vivo to a murine melanoma model. The new
delivery method has provided a possibility for cancer treatment, which could provide
insight into the potential application and development of CNT-based antisense-based
therapy.
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4.2

Introduction

RNAi was discovered in 1998 [1] and it can be induced by siRNA. It is a powerful tool
and is an attractive method for research. It can be used for treating disease specificity
with a known target, however, the clinical application of this technology is still limited.
Systematic siRNA delivery to pathological cells or tissue is still ineffective and it remains
as the bottleneck of the application [2-6].
CNT were discovered in 1991 [7] and various modifications or functionalizations have
been utilized to increase the solubility of CNT because pristine CNT (p-CNT) are not
soluble in most common solvents [8]. Water soluble CNT have been functionalized [911] and some of them have been explored for various biomedical applications [12-14].
CNT have been used for nucleic acid delivery [15-17], such as small siRNA delivery [1829]. It has been reported that CNT can gain entry into cells by a diffusion-like
mechanism, in which the CNT penetrate into cells like “nano-needles”. The cellular entry
mechanism of CNT are not limited to diffusion-like mechanism but depend on the type
and the manner in which they are functionalized and also the dimensions of CNT [30,
31].
mTOR is an important gene/protein in the downstream of PI3K/AKT pathway, which is
responsible for regulating cell growth and proliferation and its inhibitors have been used
for treating cancer in clinical trials [32]. FR are usually overexpressed in cancer [33, 34]
and it can increase the specific binding of the folic acid (FA) conjugated components to
cells which express high level of FR [35]. B16 generated melanoma expresses FA in an
in vivo mice model [36]. FA has been attached to CNT for drug delivery [37]. Previously,
we reported a non-covalently functionalized CNT with succinated PEI (IS/C) for topical
siRNA delivery. To further exploit this siRNA delivery system for delivering siRNA to
cancer, we set out to modify it with PEG and FA such that PEG can reduce the toxicity,
increase the serum stability and have a higher target specificity of the CNT/siRNA
complexes. The modified polymer and the CNT were characterized. This feasibility of
using this targeted siRNA delivery system to reduce cancer progression was examined on
a murine melanoma model.

123

4.3

Materials and Methods

4.3.1 Chemicals
Single-walled carbon nanotoubes were purchased from Nano-C (Batch PT1112-60, MA,
USA) and succinic anhydride was purchased from Alfa Aesar (MA, USA).
Polyethylenimine (PEI, Mw 15476, Mn 7893), polyethylene glycol (PEG, Mn 2000),
polyethylene glycol methyl ether (mPEG, Mn 2000), folic acid (FA), N-(3dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC), and NHydroxysuccinimide (NHS) were purchased from Sigma Aldrich (St. Louis, MO).
Solvents were purchased from Caledon (Georgetown, Canada) and other chemicals for
synthesis were purchased and used without purification from Sigma Aldrich unless
otherwise specified.

4.3.2 siRNAs
Luciferase GL2 Duplex used as scramble siRNA (siScramble) and mTOR siRNA (simTOR) were obtained from Cell Signaling Technology, Inc. (catalogue number 6332,
Danvers, MA).

4.3.3 Cell Culture
B16-F10 and KB cells were obtained from ATCC (Manassas, VA). B16-F10 cells and
KB cells were cultured with DMEM (Gibco, Life technologies, Burlington, ON, Canada)
with 10% FBS (Gibco) at 37oC and humidified atmosphere.

4.3.4 Animals
C57BL/6 mice were obtained from Charles River (Canada). All animals were housed
under pathogen-free conditions. All experiments were done in accordance to the Guide
for the Care and Use on Animals Committee Guidelines. The animal protocol was
approved by the Animal Use Subcommittee (AUS) at Western University.

4.3.5 Nuclear Magnetic Resonance (NMR) Spectroscopy
Polymer was dissolved in D2O (99%, Sigma) or CDCl3 (99%, Sigma) and was transferred
to an NMR tube. 1H nuclear magnetic resonance (NMR) spectra were obtained with
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INOVA 600 spectrometer (Agilent, Santa Clara, CA) (600MHz). The spectra were
recorded at room temperature and the D2O peak (4.7 ppm) was used as reference.

4.3.6 Size Exclusion Chromatography (SEC)
The liquid chromatography system was equipped with a Waters Separations Module
2695 (Waters, Mississauga, ON), a Refractive Index Detector (Waters 2414) and three
PLaquagel-OH 40 8µm (300x7.5mm) columns (Polymer Laboratories, Waters)
connected in series and to a PLaquagel-OH 8 µm guard column. 0.2 M ammonium
acetate/acetic acid (pH 5.3) was eluted at 1 mL/min at room temperature for 35 min/ run.
Samples were prepared at a concentration of 10 mg/mL in millique water, filtered
through 0.2 µm Supor membrane filters and injected with a 100 µl volume loop. The
calibration curve was obtained from PEO/PEG standards and the molecular weight was
calculated by Empower 3 software (Waters). The following standard molecular weights
were used: 615, 1010, 3930, 12140, 20000, 31380, 71700, 106500.

4.3.7 Synthesis of Polymers
α,ω-diamino poly(ethylene glycol) (PEG-NH2) (1b) was synthesized based on Elbert’s
method [38] and α-carboxyl-ω-methyloxy poly(ethylene glycol) (mPEG-COOH) (2b)
was synthesized based on Zalipsky’s method [39].

4.3.7.1

Synthesis of α,ω-diamino poly(ethylene glycol) (PEG-NH2)

PEG-NH2 was synthesized based on Elbert’s method [38] using α,ω-dihydroxyl
poly(ethylene glycol) (Mn 2000, Sigma Aldrich). 1H-NMR (CDCl3, 600MHz): δ 2.89 (t,
J=5.3 Hz, 4H,-OCH2CH2NH2 for both ends), δ 3.53-3.77 (m, 180H, -OCH2CH2- in PEG),
84% statistical conversion which is calculated by:
Integral of 1H D NMR peak of A   V  W/4
 100%
Integral of 1H D NMR peak of PEG/180

4.3.7.2

Synthesis of Folate Functionalized PEG (FA-PEG)

0.12 g (0.28 mmol) of folic acid, 0.7 g (3.6 mmol) of EDC HCl and 0.5 g (4.3 mmol) of
NHS were dissolved in 15 mL of DMSO. Then the mixture was stirred for 15 minutes.
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The mixture was then added dropwise into a solution of 0.46 g (0.23 mmol) of PEG-NH2
dissolved in 5 mL DMSO. The reaction mixture was stirred at room temperature
overnight and then was dialyzed using a 3.5 kDa molecular weight cut-off (MWCO)
Spectra regenerated cellulose membrane (Spectrum Laboratories, Rancho Domingo,
USA) against deionized water for 48 hours. A yellowish solid was recovered after
lyophilization (0.46 g; 81.4% in mole). 1H-NMR (D2O, 600MHz): δ 2.07-2.40 (m, 4H, CH2CH2- in glutamic acid of folic acid), 3.18-3.84 (m, 180H, -OCH2CH2- in PEG), δ
6.71-6.87 (m, 2H, ortho protons in the benzene of folic acid), δ 7.59-7.72 (m, 2H, meta
protons in the benzene of folic acid), δ 8.66-8.75 (m, 1H, proton in pteridine). Mole ratio
of folic acid modification is 0.8:1 (FA : PEG) and was calculated by: 9Integral of 1H D
NMR peak of A A  =: 9Integral of 1H D NMR peak of PEG/180=

4.3.7.3

Synthesis of Folate Functionalized PEG Succinic Acid (FAPEG-SuOH)

0.2 g (84 µmol) of FA-PEG was dissolved in 5 mL of DMSO. 0.17 g (1.70 mmol) of
succinic anhydride was dissolved in 5 mL of DMSO and was added to the FA-PEG
solution. The reaction mixture was stirred at room temperature overnight and then was
dialyzed using a 3.5 kDa MWCO regenerated cellulose membrane against deionized
water for 48 hours. A yellowish solid was recovered after lyophilization (0.12 g; 58.1%
in mole). 1H-NMR (D2O, 600MHz): δ 2.31 (s, 6H, ethylene proton from succinic acid and
ethylene proton from glutamic acid in folic acid), δ 2.64 (s, 2H, ethylene proton of
succinic acid adjacent to amide), δ 3.32-3.62 (m, 180H, -OCH2CH2- in PEG), δ 6.58-6.81
(m, 2H, ortho protons in the benzene of folic acid), δ 7.48-7.63 (m, 2H, meta protons in
the benzene of folic acid), δ 8.56-8.90 (m, 1H, proton in pteridine).

4.3.7.4

Synthesis of Folate Functionalized PEG-PEI (FA-PEG-PEI)

57 mg (22 µmol) FA-PEG-SuOH was dissolved in 5 mL DMSO. 79 mg (41 µmol) of
EDC HCl and 7.6 g (66 µmol) of NHS were added. The mixture was stirred for 15
minutes. 0.22 g (220 µmol) PEI was dissolved in DMSO and the activated FA-PEG
solution was added dropwise into the PEI solution. The reaction mixture was stirred at
room temperature overnight and then was dialyzed using a 15 kDa MWCO regenerated
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cellulose membrane (Spectrum Laboratories) against deionized water for 48 hours. A
yellowish solid was recovered after lyophilization (0.22 g; 77.8% by weight). 1H-NMR
(D2O, 600MHz): δ 2.43-3.42 (m, -NRCH2CH2- from PEI), δ 3.42-3.67 (m, 180H, OCH2CH2- in PEG), δ 6.78-6.85 (m, 2H, ortho protons in the benzene of folic acid), δ
7.62-7.70 (m, 2H, meta protons in the benzene of folic acid), δ 8.59-8.65 (m, 1H, proton
in pteridine). SEC: Mn = 15471 g/mol, Mw = 36868 g/mol, PDI = 2.38. Weight ratio of
PEI to PEG is 4.15 : 1 which is calculated as follow:


4.3.7.5

!: ! 

#$%&'()* +, -./012 3&)4 +, 56#/78 9:; +, 56# <+$+<&(=
#$%&'()* +, -./012 3&)4 +, 56>/77 9:; +, 56> <+$+<&(=

Synthesis of Folate Functionalized Succinated PEG-PEI
(FA-PEG-PEI-SA)

0.12 g (9.20 µmol) of FA-PEG-PEI was dissolved in 1 mL of water. NaCl (25 mg) was
added and the pH was adjusted to 5 by the addition of 12 M HCl. Then, 11.0 mg (0.11
mmol) of succinic anhydride was dissolved in 1 mL of DMSO and was added drop-wise
into the PEI solution. The reaction mixture was stirred at room temperature overnight and
then was dialyzed using a 15 kDa MWCO regenerated cellulose membrane against 0.5 M
NaCl solution for 4 hours followed by 44 hours with deionized water. The water was
changed 3 times per day. A yellowish product was obtained after lyophilization (0.18 g;
72.5% by weight). 1H-NMR (D2O, 600MHz): δ 2.19-3.38 (m, -NRCH2CH2- from PEI
and ethylene proton from succinic acid), δ 3.44-3.67 (m, 180H, -OCH2CH2- in PEG),
6.68-6.81 (m, 2H, ortho protons in the benzene of folic acid), δ 7.57-7.66 (m, 2H, meta
protons in the benzene of folic acid), δ 8.57-8.65 (m, 1H, proton in pteridine). Percentage
of amine conversion is 7.3% which is calculated by the following equation:
]^_`abcd ef -g h`ci 9jklmnopp]^]p cp]q ]^ rls=/]^_`abcd ef -g 9jkl h`ci ]^ jkr/jkl=
]^_`abcd ef -g 9jklmnopp]^]p cp]q h`ci ]^ rls=

4.3.7.6

 100%

Synthesis of α-carboxyl-ω-methyloxy ether poly(ethylene
glycol) (mPEG-COOH)

2b was synthesized based on Zalipsky’s method [39] using methyloxy ether
poly(ethylene glycol) (Mn 2000, Sigma Aldrich). Sodium was used instead of potassium
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tert-butoxide. 1H-NMR (CDCl3, 600MHz): δ 3.38 (s, 3H, -OCH3), δ 3.58-3.82 (m,
180H,OCH2CH2 in PEG), δ 4.15 (s, 2H) 99% conversion.

4.3.7.7

Synthesis of PEG-PEI

50 g (25 µmol) of PEG-COOH was dissolved in 5 mL DMSO, and then 97 mg (0.5
mmol) of EDC HCl and 61 mg (0.53 mmol) of NHS were added. The mixture was stirred
for 15 minutes. 0.25 g (25.4 µmol) PEI was dissolved in DMSO and the activated PEG
solution was added dropwise into the PEI solution. The reaction mixture was stirred at
room temperature overnight and then was dialyzed using a 15 kDa MWCO regenerated
cellulose membrane against deionized water for 48 hours. White solid was recovered
after lyophilization (0.28 g; 93.2% by weight). 1H-NMR (D2O, 600MHz): δ 2.44-3.48 (m,
-NRCH2CH2- from PEI), δ 3.66-3.70 (m, 180H, -OCH2CH2- in PEG), δ 3.92 (s, 2H, OCH2CO-). SEC: Mn = 17515 g/mol, Mw = 30693 g/mol, PDI = 1.75. Weight ratio of PEI
to PEG is 4.15 : 1 which is calculated as follow:


4.3.7.8

!: ! 

#$%&'()* +, -./012 3&)4 +, 56#/78 9:; +, 56# <+$+<&(=
#$%&'()* +, -./012 3&)4 +, 56>/77 9:; +, 56> <+$+<&(=

Synthesis of PEG-PEI-SA

137 mg (14.4 µmol) of PEG-PEI was dissolved in 10 mL H2O. NaCl (0.25 g) was added
and the pH was adjusted to 5 by the addition of 12 M HCl. Then, 13 mg (1.3 mmol) of
succinic anhydride was dissolved in 10 mL of DMSO and was added drop-wise into the
polymer solution. The reaction mixture was stirred at room temperature overnight and
then was dialyzed using a 15 kDa MWCO Spectra regenerated cellulose membrane
against 0.5 M NaCl solution for 4 hours followed by 44 hours with deionized water. The
water changed 3 times per day. The product was then lyophilized and a white solid was
recovered (0.18 g; 118% by weight). 1H-NMR (D2O, 600MHz): δ 2.38-3.40 (m, NRCH2CH2- from PEI), δ 3.66-3.68 (m, 180H, -OCH2CH2- in PEG). Percentage of
amine conversion is 7.2% which is calculated by:
]^_`abcd ef -g h`ci 9jklmnopp]^]p cp]q ]^ rls=/]^_`abcd ef -g 9jkl h`ci ]^ jkr/jkl=
]^_`abcd ef -g 9jklmnopp]^]p cp]q h`ci ]^ rls=

 100%
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4.3.7.9

Non-covalent Functionalization of SWCNT by FGIS or GIS

5 mg of FGIS or GIS was weighed in a tube and 20 mL of deionized water was added to
dissolve the polymer. Then, 5 mg of CNT was added into the polymer solution. The
solution was sonicated for 15 minutes at 60 degree Celsius and then vortexed. This step
was repeated 6 times. The undissolved CNT were removed by vacuum filtration with a
0.22 µm Nylon filter. Then, the unbound polymer was removed by using ultra-15
centrifugal filter units (100 kDa MWCO, Amicon, Billerica, MA). The concentrated CNT
solution was centrifuged to remove solid residues and then lyophilized and a grey
yellowish or a grey solid was recovered (22.1% for FGIS/C and 25.9% for GIS/C). The
recovery was calculated as follow:




 




tC/  C/  
 100%
  
tC  C

4.3.8 Transmission Electron Microscope (TEM)
FGIS/C or GIS/C was dissolved in water and dropped onto a copper grid. After 20
minutes, the solution was removed and the grid was dried under air. The sample was
analyzed by a Philips CM 10 Transmission Electron Microscope (Philips, Eindhoven, the
Netherlands) operating at 80 kV with a 40 µm aperture.

4.3.9 Gel Shift Assay
Equal volumes containing 0.5 µg of siRNA and the desired amount of FGIS/C or GIS/C
were mixed and incubated for 30 minutes. The resulting complexes were analyzed by
electrophoresis at 100 mV using 1.5% agarose gel and EtBr in TAE buffer. After 20
minutes, the gel was removed, visualized and the picture was recorded with FluroChem
M (Protein simple, Santa Clara, CA).

4.3.10

Zeta Potential

FGIS/C/siRNA or GIS/C/siRNA complexes were prepared by mixing equal volumes
containing siScramble (5 µg) and desired amount of CNT solution, then the resulting
solution was incubated for 30 minutes. The solution was then transferred to a disposable
capillary cell and was analyzed using a Malvern Zetasizer Nano ZS (Malvern,
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Worcestershire, UK, He-Ne laser (633nm)). An energy output of 10 mW with automatic
laser attenuation was used for measurements. The mean and standard deviation of zeta
potentials were calculated with two measurements of the average of 10 runs using
automatic algorithm.

4.3.11

Cellular Uptake of siRNA by KB cells

KB cells were seeded in a 24-well plate with a density of 5x104 cells/well in 0.5 mL
respective culture media for folate containing media. The same cell density was used for
folate free condition. The cells were washed 3 times with PBS and then resuspended
folate free RPMI 1640 (Gibco). Then, the cells were incubated overnight in 37 oC and
humidified atmosphere. FGIS/C/siRNA and GIS/C/siRNA complexes were made by
mixing equal volumes of Cy3-labeld si-mTOR and 5 times FGIS/C or GIS/C (w/w), 2
µg/mL of siRNA was used for transfecting the cells. The solution was incubated for 1 hr.
Then the FGIS/C/siRNA and GIS/C solutions were transferred to serum containing
media. 1 hr after transfection, the cells were washed by PBS, trypsinized and analyzed by
flow cytometry.

4.3.12

Cell Proliferation of B16-F10 by MTT

B16-F10 cells were seeded in a 6-well plate with density of 2.4x105 cells/well in 2 mL
culture media. 2 µg/mL of lipofectamine 2000 and 1 µg/mL of si-mTOR was used for
silencing B16-F10 cells. 24 hours after gene silencing, the cells were trypsinized and
reseeded into a 96 well plate (500 cells per well). The cells were then incubated for 96
hours and media were removed. MTT (Calbiochem, Gibbstown, NJ) in serum free media
(20 mg/mL) was added and incubated for 3 hours. The media were removed and DMSO
was added to dissolve the crystals. The absorbance at 570 nm was recorded using a Tecan
Infinite M1000 PRO (Manndorf, Switzerland).

4.3.13

Cytotoxicity of FGIS/C and GIS/C in B16-F10 cells

B16-F10 cells were seeded in a 24-well plate with density of 5x104 cells/well in 500 µL
culture media 24 hours before transfection. The media were replaced with culture media
containing the desired amount of FGIS/C or GIS/C. The cells were then returned to
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incubation for 24 hours. The media were collected and the cells were typsinized,
collected and re-suspended in PSB with 2% FBS and 5 µg/mL 7AAD. The cells were
then analyzed with flow cytometry. Percentage of cell death was calculated by the 7AAD
positive cells in the treated cells minus the 7AAD positive cells in the untreated cells
which were considered as the background cell death.

4.3.14

In vivo Delivery of siRNA with FGIS/C and GIS/C to
Melanoma Bearing Mice

Melanoma bearing mice were generated by inoculating 2x105 B16-F10 cells
subcutaneously into C57BL/6 mice. 7 days after tumor inoculation, 100 µg of Cy3labelled siRNA and 300 µg of FGIS/C or GIS/C were injected into the mice
intravenously. 24 hours after injection, the mice were sacrificed and the tumor was
removed and frozen in OCT. The tumor was crycosectioned, stained with H&E and
observed under fluorescence microscope (Olympus BX51, Olympus Canada Inc., ON,
Canada).

4.3.15

Treatment of Melanoma Bearing Mice using FGIS/C and
mTOR siRNA

Melanoma bearing mice were generated by inoculating 2x105 B16-F10 cells
subcutaneously into C57BL/6 mice. 4 days after tumor inoculation, mice were
randomized and 300 µg of FGIS/C or GIS/C and 100 µg siRNA (si-mTOR or
siScramble) in 5% glucose were injected into mice. There were 4 groups of mice,
untreated mice, FGIS/C/si-mTOR, FGIS/C/siScramble and GIS/C/si-mTOR. The tumor
sizes were measured with a caliper every two days and the mice were injected with
CNT/siRNA once each week. 20 days after tumor inoculation, the mice were sacrificed
and tumors were removed. The tumor weights were measured with a 2-digit electronic
balance. Tumor was frozen for later use. Tumor was frozen for later use.

4.3.16

Statistics

Data were expressed as mean± standard error or standard deviation of the mean and the
results were analyzed a by one way ANOVA followed by Dunnett's test as post-test,
student’s t-test or two way ANOVA followed by Bonferroni’s test as post-test. p < 0.05
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was considered statistically significant. All the data analysis was performed in GraphPad
Prism.

4.4

Results

4.4.1 Synthesis and Characterization of FA-PEG-PEI-SA (FGIS) and
FA-PEG-PEI-SA/CNT (FGIS/C)
The synthesis of FA-PEG-PEI-SA (FGIS) was performed as shown Fig. 4.1. First,
hydroxyl-terminated PEG was converted to the amine-terminated PEG by first
mesylation and then displacement of the mesylate with ammonia according to a
previously reported procedure [38]. The amine functionalized PEG was then reacted with
1 equivalent of folic acid in the presence of the coupling agent DEC to provide FA-PEG.
The remaining amine on FA-PEG was then reacted with succinic anhydride to provide
FA-PEG-SuOH. It should be noted that as the initial reaction with folic acid provides a
statistical mixture of PEG with two amines (~25%), one amine and one folic acid
(~50%), and finally two molecules of folic acid (~25%), the resulting FA-PEG-SuOH
was also expected to be a statistical mixture containing PEG with two succinic anhydries
(~25%), one succinic hydride (~25%)and one folic acid (~50%) and two molecules of
folic acid (~25%). FA-PEG-SuOH was then coupled to PEI to provide FGI, and finally
this PEI conjugate was reacted with succinic anhydride to provide FGIS. 1H-NMR
spectroscopy of FGIS showed the successful modification (Fig. 4.3). The weight ratio
between PEI to PEG was determined to be 4.1 and the percentage of succination was
7.3% which was determined based on the integrals of the PEI peaks (δ 2.5-3.5) before
succination and after succination because of the overlap of PEI and succinic acid peaks.
FGI was analyzed by SEC (Fig. 4.4) and was found to have a Mn of 15471 and Mw of
36868 in comparison to the starting PEI, which had a Mn of 7893 and a Mw of 15476. It is
likely that a small degree crosslinking occurred during the conjugation of FA-PEG-SuOH
to the PEI, but this should not be detrimental to the CNT binding or transfection
capabilities. The detail of the molecular weight was summarized in Table 4.1.
The synthesis of PEG-PEI-SA (GIS) was performed as shown in Fig. 4.2. Methoxylated
PEG was converted to the carboxylic acid PEG-terminated PEG by reacting the alcohol
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with potassium to form an alkoxide and then reacted with the tert-butyl
butyl bromoacetate
with reference
erence to a previous report [39].. The PEG acid was then reacted with PEI by
EDC coupling to provide PEG
PEG-PEI. PEG-PEI
PEI was then reacted with succinic acid to
provide GIS. 1H-NMR
NMR spectroscopy of GIS sh
showed
owed the successful modification (Fig.
4.3). The weight ratio between PEI to PEG was determined to be 4.2 and the percentage
of succination was 7.2% which was again, determined based on the integrals of the PEI
peaks (δ 2.5-3.5)
3.5) before succination and afte
afterr succination because of the overlap of PEI
and succinic acid peaks. PEG
PEG-PEI
PEI was analyzed by SEC (Fig. 4.4) and was found to have
a Mn of 17515 and a Mw of 30693 (Table 4.1).

Figure 4.1 Scheme of synthesis of FA-PEG-PEI-SA (FGIS)
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Figure 4.2 Scheme of synthesis of PEG
PEG-PEI-SA (GIS)
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Figure 4.3 1H-NMR of FGIS and GIS
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Figure 4.4 SEC of PEI, FGI and PEG-PEI
SEC of PEI, FGI and PEG-PEI. PEI on the top, followed by FGI and PEI-PEI. The
bottommost figure is the overlay of all chromatograms. The polymers were eluted by a
0.2 M acetic acid/ammonium acetate (pH 5.3) buffer system with PL aquagel-OH column
and were analyzed by RID.

Mn

Mw

PDI
(Mn/Mw)

FGI

15471

36868

2.38

PEG-PEI

17515

30693

1.75

Table 4.1 Calculated molecular weight of FGIS and GIS by SEC
After the non-covalent functionalization of CNT by FGIS and GIS, TEM (Fig. 4.5)
showed that FGIS/C and GIS/C were singly dispersed with a length of approximately 500
nm which is shorter than the claim of the manufacturer. CNT were shortened in the
process.
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Figure 4.5 TEM micrograph of GIS/C and FGIS/C
Minimum amount of CNT solution
on was added to the copper grid and incubated for 20
minutes. The excessive solution was then removed, the grid is air-dried and the
th samples
were observed under TEM
TEM. The length of the GIS/C (right) and FGIS/C (left) are around
100-600 nm.

The siRNA binding capacity of FGIS/C and GIS/C were demonstrated by gel shift assay.
The capacities of the siRNA condensation of both CNT were tested. Free
ree siRNA migrates
along the gel while siRNA complexed with CNT will be slowed down or totally ceased.
Also,, siRNA cannot bind to ethidium bromide effective
effectively after it binds to the cationic
CNT and thus the fluorescence intensity of the bound siRNA would be reduced.
reduce The
results showed that the ratio of FGIS/C required to inhibit the migration of siRNA is 2:1
(w/w) while GIS/C is 1:1 (Fig. 4.6).
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Figure 4.6 Gel shift assay of siRNA with FGIS/C and GIS/C
Electrophoresis was done on the samples and the gel was taken out for visualizing the
bands. The weight
ht ratio of siRNA condensed by FGI
FGIS/C is 2:1 and by GIS/C is 1:1.
1:1

The stability of FGIS/C or GIS/C and siRNA complexes was studied using zeta potential.
The higher the magnitude of the zeta potential, the more stable the complexes would be,
due to electrostatic repulsion. The result showed that FGIS/C/siRNA has a zeta potential
range from 35.8 mV to 48.5 mV while GIS/C/siRNA the zeta poten
potential
tial from 53.9 to 62.9
as GIS/C to siRNA ratio increases. Overall, FGIS/C/siRNA complexes have a lower zeta
potential than GIS/C/siRNA
IS/C/siRNA complexes probably due to the incorporation of folic acid.
Nevertheless, they have high zeta potential which is an indica
indicator of good colloidal
stability (Fig. 4.7).
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Figure 4.7 Zeta potential of FGIS/C/siRNA and GIS/C/siRNA
The sample was dispersed in deionized water and analyzed with Zetasizer. The
experiment was done with 10 runs and the error bar is standard deviation. Four
CNT:siRNA (w/w) ratios were tested. n=2

4.4.2 In vitro siRNA Delivery with FGIS/C and GIS/C
The cellular uptake difference between folic acid bearing CNT (FGIS/C) and non-folic
acid bearing CNT (GIS/C) were compared in KB which is known to express high level of
FR. The result showed that there is a slight increase of siRNA uptake after attaching FA
(Fig. 4.8).
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Figure 4.8 Cellular uptake of Cy3-labelled siRNA by KB
KB cells were transfected with Cy3-labelled siGAPDH, and then the cells were returned
to incubation for 1 hour. Then cells were washed, typsinized, collected and re-suspended
in PBS with 2% FBS. The cells were then analyzed with flow cytometry. n=3; error
bar=SEM

4.4.3 In vitro Cytotoxicity of FGIS/C and GIS/C
The cytotoxicity of FGIS/C and GIS/C were examined in B16 cells with flow cytometry
after 7AAD staining. The cytotoxicity is low up to the concentration of 10 µg/mL (< 10%
cell death). Their cytotoxicities are similar up to 30 µg/mL, no significant difference
between FGIS/C and GIS/C. Significant differences between FGIS/C or GIS/C to IS/C
were found between concentrations 20 µg/mL and 30 µg/mL. (Fig 4.9)
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141

100

FGIS/C
GIS/C
IS/C

80
60

*
*

40
20
0
2
-20

5

10

20

30

conc. (µg/mL)

Figure 4.9 Cell proliferation of B16-F10 by MTT
B16-F10 cells were treated with desired amount of FGIS/C or GIS/C and then the cells
were returned to incubation for 24 hours. Media were collected and the cells were
typsinized, collected and re-suspended in PSB with 2% FBS and 5 µg/mL 7AAD. The
cells were then analyzed with flow cytometry. Percentage of cell death was calculated by
the 7AAD positive cells in the treated cells minus the 7AAD positive cells in the
untreated cells. IS/C data from chapter 3 was used for comparison. Asterisk indicated
p<0.05 by two way ANOVA with Bonferroni post-tests. n=3; error bar=SEM

4.4.4 In vitro Cell Proliferation of mTOR siRNA
In vitro cell proliferation of mTOR siRNA was examined with lipofectamine 2000.
Previously it has been reported that CNT would interact with MTT [40] and so,
lipofectamine 2000 was used instead of FGIS/C or GIS/C. Significant reduction of cell
proliferation (75%) was found in si-mTOR treated B16 cells. (Fig. 4.10)
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Figure 4.10 Cell proliferation of B16-F10
B16-F10 cells were transfected with si-mTOR and lipofectamine 2000 and after 24 hours,
cells were trypsinized and 500 cells were seeded into 96 wells plates. The cells were then
incubated for additional 96 hours. Then media were replaced with serum free media with
10% MTT and the cells were incubated for 3 more hours. Media were removed, DMSO
was added to wells and the absorbance at 570 nm was recorded. n=6; error bar=SEM (p
value was calculated with Student’s t-test)

4.4.5 In vivo Delivery of siRNA with FGIS/C and GIS/C to Melanoma
Bearing Mice
It has been reported that CNT localize around tumor. Also, PEG could increase the
circulation half-life of the siRNA vehicle and thus, it is expected that the siRNA are more
likely to localize around tumor by enhanced permeability and retention (EPR) effect. To
examine whether the conjugation of folic acid is beneficial to the CNT we functionalized.
We set out to use FGIS/C and GIS/C to test the difference between the two. It is well-
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known that B16-F10 overexpress FR and it was used for tumor inoculation. The
differences between FGIS/C and GIS/C in delivering siRNA into tumor were examined
by intravenous injection into melanoma bearing mice. The fluorescence picture showed
that the localization of siRNA in tumor was more for the FGIS/C/siRNA treated mice
than the GIS/C/siRNA treated mice (Fig. 4.11). Therefore, there is evidence that CNT or
PEG conjugated delivery vehicle localized in the tumor more than those without CNT or
PEG. FA conjugation can further increase the localization of the vehicle to FR expressing
tumor. FGIS/C is a more specific siRNA delivery vehicle for tumor compared to GIS/C.
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Figure 4.11 In vivo uptake of tumor of FGIS/C/siRNA GIS/C/siRNA
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2 days before the mice were sacrificed (18th day). 100 µg of Cy3-labelled siRNA and 300
µg of FGIS/C or GIS/C were injected into the mice by tail vein injection. The mice were
sacrificed 48 hours after injection and the tumor was removed and frozen in OCT. The
tumor was crycosectioned and the samples were observed under fluorescence
microscope. H&E staining was done to show the tumor which has an enlarged nucleus
and reduced cytoplasm.

4.4.6 Treatment of Melanoma Through Intravenous siRNA Delivery of
mTOR siRNA Using FGIS/C
FGIS/C/siRNA localized more in the tumor compared to GIS/C/siRNA as demonstrated,
therefore, we set out to test if it is the same in treating tumor with siRNA. mTOR is
responsible for cell growth and proliferation. To test the therapeutic effect of using
mTOR siRNA to inhibit tumor progression, we treated melanoma-bearing mice with
FGIS/C/si-mTOR.
The tumor size is significantly different for the FGIS/C/si-mTOR from tumor treated with
FGIS/C/siScramble. The tumor growth was inhibited significantly for the FGIS/C/simTOR group. There is no significant difference between untreated tumor and tumor
treated with FGIS/C/siScramble (Fig. 4.12), however, there is also no significant
difference between FGIS/C/si-mTOR and GIS/C/si-mTOR. A similar trend was observed
in the average tumor weight when the mice were sacrificed on day 20. The final tumor
weight was not significantly different between untreated mice and FGIS/C/siScramble
treated mice while the FGIS/C/si-mTOR and GIS/C/si-mTOR treated group was
dramatically reduced compared to scramble control (Fig. 4.13). Significant difference of
tumor volume was found from 16th day, to 18th day and 20th day between FGIS/C/mTOR
and FGIS/C/siScramble. Again, the tumor weight between FGIS/C/si-mTOR and
GIS/C/si-mTOR treated group have no significant difference. However, Western blot
data showed that the mTOR down-regulation by FGIS/C/si-mTOR is higher than
GIS/C/si-mTOR (Fig. 4.14). The percentage of protein downregulation was 65% for
FGIS/C/si-mTOR while it was 18% for GIS/C/si-mTOR (Fig. 4.15). These data imply
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that FGIS/C is superior to GIS/C in delivering siRNA in vivo and thus the mTOR
expression in tumor of FGIS/C/si-mTOR treated mice is lower than that of GIS/C/simTOR treated mice, however, both FGIS/C/si-mTOR and GIS/C/si-mTOR reduced the
tumor progression to a similar level.
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Figure 4.12 Tumor size of tumor bearing mice intravenously injected with FGIS/C,
GIS/C and siRNA
4 days after the mice were inoculated with tumor, the mice were injected intravenously
with FGIS/C/si-mTOR solution for every 7 days until 20th day for sacrifice. The tumor
size of mice was estimated by the length and width of the tumor by a caliber in nearest
0.5 mm. The sizes were calculated with π(LxW2)/6. 2-way ANOVA with Bonferroni test
as post-test showed that significant difference between the scramble control and the
FGIS/C/si-mTOR treated mice. Significant difference of tumor volume begin from 16th
day (p<0.05), to 18th day (p<0.01) and 20th day (p<0.001) between FGIS/C/mTOR and
FGIS/C/siScramble. n=7 for untreated mice, n=6 for FGIS/C/si-mTOR and
FGIS/C/siScramble and n=5 for GIS/C/si-mTOR; error bar=SEM.
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Figure 4.13 Tumor weight of tumor bearing mice intravenously injected with
FGIS/C, GIS/C and siRNA
The tumor of mice was removed and weighted on the day when the mice were sacrificed
(Day 20). n=7 for untreated mice, n=6 for FGIS/C/si-mTOR and FGIS/C/siScramble and
n=5 for GIS/C/si-mTOR; error bar=SEM. (Asterisk indicated p<0.05, samples analyzed
by 1-way ANOVA followed by Dunnett’s test as post-test by comparing with siScramble
group)
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Figure 4.14 Western blot of the tumor samples
The tumor samples were homogenized and the protein was isolated with RIPA buffer for
western blot. mTOR was analyzed and beta actin was used as internal control.
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Figure 4.15 Relative mTOR expression on protein level
The band intensity of western blot was quantified with photoshop. n=3 error bar=SEM
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(Asterisk indicated p<0.05, samples analyzed by 1-way ANOVA followed by Dunnett’s
test as post-test by comparing with siScramble group)

4.5

Discussion

Novel non-covalently functionalized SWCNT were developed for siRNA delivery in
vivo. This novel siRNA delivery system is modified based on our previously reported
CNT delivery system with PEG and folic acid. PEG could reduce the toxicity, enhance
the colloidal stability and increase the circulation half-life of the conjugated component
[41-43]. It is very important for in vivo systematic delivery to cancer because the
accumulation of it to the tumor will be increased due to EPR effect [44]. Similar
observation when CNT were used for drug delivery to tumor [12]. Also, PEGylation
reduces the clearance of particles by RES [41].
FA is essential for DNA synthesis as well as the biosynthesis of S-adenosyl methionine,
an essential chemical for methylation which is important for various biochemical
reactions [34]. Cancer cells usually overexpress FR and which can be exploited for
targeted siRNA delivery. Therefore, we set out to attach FA to CNT with PEG. FA can
be attached to one end of PEG for cancer cell targeting and the succinated PEI can be
attached to the other end for dispersing the CNT as well as condensing siRNA by
electrostatic interaction. To reduce the self-crosslinking succinated PEI, succinic
anhydride modification on the amine of PEI was done in the final step. FA was attached
to PEG-NH2 by EDC/NHS coupling. Dialysis was used as purification in most reactions
for removing most of the unreacted folic acid, succinic anhydride, EDC and NHS.
Precipitation in diethyl ether method was attempted for PEG-FA but it was not successful
probably due to high solubility of PEG in DMSO/diethyl ether mixture. FA-PEG-NH2
was reacted with succinic anhydride to form FA-PEG-SuOH and then reacted with the
amine of PEI by EDC/NHS coupling to form FA-PEG-PEI. Then, it was reacted with
succinic anhydride to form FA-PEG-PEI-SA. For PEG-PEI-SA (GIS), PEI was attached
to mPEG-COOH by EDC/NHS coupling. Then PEG-PEI was reacted with succinic
anhydride to form PEG-PEI-SA. The conjugation of folic acid to one end of PEG was
done by stoichiometric control with EDC/NHS coupling. The γ-carboxyl group of
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glutamic acid in folic acid reacts preferentially with the amine because it has a higher
reactivity than the α-carboxyl group [45-47]. Succination was done after the conjugation
of PEI to FA-PEG which is to avoid the self-crosslinking of succinated PEI during
EDC/NHS coupling with FA-PEG. However, there is still crosslinking observed in the
SEC (Fig. 4.4). The small peak at ~15 min indicated there is a high molecular weight
species which is probably the crosslinked polymer, however, the percentage is relatively
low. The degree of succination is similar for both polymers. CNT with FA, FGIS/C and
CNT without FA, GIS/C were made by non-covalent functionalization.
One interesting observation is that, the ratios to condensing the siRNA for GIS/C and
FGIS/C are different despite the degree of succination of the polymers are similar. GIS/C
has a higher capacity to condense siRNA while FGIS/C has a lower capacity. One of the
possible reasons is the conjugation of FA to the PEG. FA has a pKa of 4.65 and it is
deprotonated at physiological condition. It is highly possible that the FA reduced the
siRNA condensing capacity. Excluding for the amine attached to succinic acid and to
PEG, the modified PEI has an average of 16.8 protonable amines for each PEG attached.
FA is attached to the other end of PEG which is far away from the PEI/CNT core. FA is
close to the surface and therefore, the negatively charge FA affect the overall siRNA
binding capacity of the FGIS/C is more significant than the PEI. Also, succinic acid
neutralizes the charge on PEI and only a portion of the amines in PEI are protonated at a
given pH. A small amount of folic acid induced significant changes on the siRNA
binding capacity.
The zeta potentials also indicated similar observation as in gel shift assay, regardless of
the ratios, the zeta potential of GIS/C/siRNA is higher than FGIS/C. It is expected that if
the siRNA delivery is driven principally by zeta potential, GIS/C should outperform
FGIS/C. KB, a cell line which known to express high level of FR was used for testing the
difference in vitro, there is slight increase of siRNA uptake for FGIS/C, however, there is
no statistical significant difference. It is possible that the in vitro cellular uptake is
dominated by the magnitude of zeta potential. Another possible reason is that the media
recommended by ATCC for KB cells are not RPMI 1640 which was the only FA free
media we can obtain commercially, the cells behaviors might be changed as well as the
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FR expression profile and cellular uptake activity after 1 day incubation. A further
examination on the FR expression profile and cellular uptake behaviors should be studied
for understanding the cellular uptake behavior.
The importance of a targeting moiety in delivering siRNA was reflected in vivo siRNA
localization by systematic administration. For in vitro system, charged-mediated uptake
plays a more important role than receptor-mediated uptake and therefore there is no
difference in vitro. It is because the complexes are in the well and they will not be
eliminated or removed from the system. Also, the concentration of siRNA is higher than
in vivo. Furthermore, for in vivo system, they can be cleared away by the RES, trapped by
other organs or excreted from the body. Therefore, we set out to test the targeting
capacity of FGIS/C in vivo. A recent study proved that systematic mTOR inhibition
reduced the tumor growth but weight reduction was not observed [48]. Therefore,
systematic mTOR inhibition is not likely to induce intolerable toxicity to the mice. CNT
with mTOR siRNA was administrated systematically. There is more localization of
siRNA for the mice treated with FGIS/C/si-mTOR compared to GIS/C/si-mTOR. The
localization of siRNA leads to reduction in mTOR expression in protein level which was
demonstrated by western blotting. Therefore, for in vivo delivery to tumor, chargedmediated uptake is less efficient to localize the siRNA effectively into the tumor
compared to a more specific receptor-mediated uptake. Even though both PEG and CNT
enhanced the localization of the complexes to tumor by EPR effect, attachment of FA is
beneficial for siRNA delivery for gene downregulation. A recent in vivo doxorubicin
delivery study to tumor with multiple wall carbon nanotubes by Mehra et. al. [49] showed
slightly improved localization and therapeutic effect. Nevertheless, FGIS/C has a higher
capacity to deliver siRNA in vivo to the tumor in vivo and it induces gene
downregulation.
It is interesting that the inhibition of mTOR in protein level is significantly higher for
FGIS/C/si-mTOR compared to GIS/C/si-mTOR, however, the tumor growth inhibition of
FGIS/C/si-mTOR and GIS/C/si-mTOR do not have significant difference. The tumor
growth inihibition of FGIS/C/si-mTOR and GIS/C/si-mTOR were significant higher
compared to FGIS/C/siScramble and untreated mice. Therefore, the growth inhibition is
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not due to the FGIS/C alone. It is more likely that the downregulation of mTOR inhibited
the tumor growth for FGIS/C/si-mTOR. The therapeutic outcome of the FGIS/C and
GIS/C are similar and it is possible that a more frequent treatment of mice would reveal
the difference between the two. One possible explanation is that the GIS/C/si-mTOR gain
into some cells or tissue which might affect the tumor growth, it might localize around
the tumor by EPR and it downregulated the mTOR of blood vessel such that the nutrient
supply to the tumor is reduced and at the end, the size of the tumor. Another possibility
is that there is no difference in the distribution of the siRNA between FGIS/C and GIS/C
in the treated tumors as a whole but the localization of siRNA in the tumor cells which
express high level of FR. The tumor is a mixture of high FR and low FR expressing cells
and therefore, the dominant factor for reducing the tumor progression is zeta potential.
Recent studies found out that Akt/mTOR interact with RAF/EKR pathway and which
promotes melanoma growth [50-52]. Multiple gene targeting such as Braf/EKR/mTOR is
more promising and it is well known that rapamicin can only inhibit mTORC1 but not
mTORC2 [32, 53-55] and resistance to Braf inhibitors has been found [56, 57]. Although
there are inhibitors for kinase function inhibition of both mTORC1 and mTORC2 [48],
siRNA specifically downregulate a gene and thus all of the protein function, which can
guarantee the mTOR function is lost and less likely to develop undesirable side effect or
drug resistance. Also, siRNA might not get into all kind of cells such as difficult to
transfect cells like T cells or dendritic cells which might reduce the off-targeting side
effect.

4.6

Conclusion

A novel and efficient non-covalently functionalized CNT for cancer siRNA delivery was
developed. PEI based polymers with folic acid and without folic acid were synthesized
and they were used for functionalize CNT. The polymer/CNT composites were
characterized and their siRNA delivering capacities were accessed in vivo in a murine
melanoma model. Tumor progression was suppressed and gene silencing was found in
vivo on the protein level. However, the tumor size and tumor weight after treatment
between FA bearing CNT and CNT without FA has no significant difference.
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Chapter 5

5

General Discussion
5.1

Discussion of CNT as siRNA Delivery Vector

The core research question of this thesis is: is CNT a good candidate for siRNA delivery?
This question is based on the validity of the premise: RNAi is a good approach for new
generation therapeutics. If the premise is not true, no matter how efficient CNT based
siRNA delivery vectors are developed, it is meaningless in providing alternative
therapeutics to our current ones. Certainly, the examination of CNT in siRNA delivery
alone cannot answer this question and the experimental data in chapter 2-4 might not
provide a clear answer. Also, there is a hidden research question based on the first
question: what is the benefit of CNT for siRNA delivery or drug delivery? In other
words, what are the possible benefits CNT could provide such that it would get thought
the barriers in: reaching target cells/tissue, cellular entry, cellular trafficking and finally,
siRNA release for inducing the PTGS.
The scope of the studies throughout the thesis focused on utilizing the previously
reported knowledge on siRNA delivery system to develop a CNT based vector for
biological applications. Two different kinds of polymers were synthesized and one of
these was used to attach folic acid which is used as a targeting ligand. Two of the
functionalized CNT were used in a cancer model. The thesis chapters are summarized as
follow:
•

Chapter 2: DGI/C was used for in vitro and in vivo systematic siRNA delivery

•

Chapter 3: IS/C was used for in vitro and topical siRNA delivery; a mouse
cutaneous melanoma model was used for examining the therapeutic potential of
topical application of IS/C was demonstrated with siBraf.

•

Chapter 4: FGIS/C was used for systematic siRNA delivery; a mouse cutaneous
melanoma model was used for examining the therapeutic potential of systematic
administration of FGIS/C was demonstrated with si-mTOR.
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In these chapters, we tried to explore the feasibility of utilizing CNT for siRNA delivery.
As discussed in chapter 1, delivery of siRNA or nucleic acids is difficult in general,
especially in vivo. siRNA delivery in vitro can be carried out easily using commercially
available reagents produced by various company like Invitrogen, Roche, Thermo
scientific, Cell Signaling Technology, Santa Cruz, Polyplus and more. Most of the
reagents are based on a lipid based recipe. Most of the reagents cannot deliver siRNA in
vivo efficiently and therefore, an alternative method for siRNA delivery is necessary.
The use of CNT and PEI are the core of the three siRNA delivery system studied in this
thesis and their efficacies were examined. PEI modification is necessary for effective
siRNA delivery while siRNA modification into sticky siRNA can mediate higher gene
silencing [1]. Here, we demonstrated the method to modify the delivery vector instead of
the siRNA for the delivery. CNT-based delivery vector can gain entry into the cells
effectively but it has to be modified before it can be singly dispersed in water. The
method used in this thesis for the CNT dispersion is based on non-covalent method and it
was carried out with a sonicator. The efficiency of dispersing the CNT is low (20-30%
w/w) when compared to covalent methods. An interesting behavior of CNT is that
sonication would shorten the CNT beyond a certain time [2]. Another interesting
observation reported was that, the degree of functionalization depends on the power of
sonication instead of the duration of sonication [3]. Therefore, it is highly possible that
only the shortened CNT can be dispersed. Also, the CNT dispersed is highly dependent
on the power of the sonicator. Therefore, the short CNT is easier to be dispersed than the
long CNT. In the report of Kam [4], the CNT was 50-300 nm, however, we found that the
length of the CNT for DGI/C, IS/C, FGIS/C and GIS/C, the length are around 200-1000
nm. One of the most probable explanation is the power of the sonication in Kam’s report
was higher than the one reported here. However, the sonication power was not mentioned
in their paper. One possible explanation is that the CNT Kam et. al. used has a wider
length distribution while the CNT we obtained has a narrower length distribution and
thus, the larger CNT was removed by centrifugation while only smaller CNT were
preserved.
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CNT has been used for nucleic acids delivery. The criterion for an ideal delivery system,
as mentioned before, is that the delivery system should act like a “magic bullet” such that
it targets the pathological tissue without affecting the host. However, in practice, what we
consider is: is the harm to the patient outweighed by the benefit to the patient? The
conventional small molecular cytotoxic drugs (for example cisplatin) almost kill all kinds
of cells indiscriminately. Theoretically, systematic delivery of untargeted anti-cancer
drug is not a good delivery method. However, it is an effective way to reduce the
progression of cancer. In other words, the benefit of using the drug outweighed the side
effects; it is acceptable in clinical settings as the best available option. Applying the same
rationale to CNT prepared in this thesis provides goals. If the gene silencing mediated by
the CNT delivered siRNA is not higher than the siRNA alone, it is not a good delivery
system because it lacks the functional improvement. Another one is if the gene silencing
induced by CNT mediated delivery of siRNA was worse than the commercially available
reagents, then it is not the best option as there are no advances in tackling the technical
barriers. For the first goal, as we observed from the literature and the results throughout
the study, CNT increased the siRNA uptake in cells [4] and enhanced cancer drug
delivery [5]. Therefore, it is justified to use CNT for siRNA delivery. For the second
goal, the CNT studied throughout these studies were better than some of the
commercially available reagents like DGI/C is able to deliver siRNA to the liver and
induces notable gene silencing; IS/C is able to deliver siRNA via topical application and
FGIS/C and GIS/C are able to deliver siRNA to tumors. Therefore, it is justified to use
CNT for siRNA delivery in RNAi therapy.
The interesting “nano-needle” effect was observed and it is interesting in studying the
cellular uptake mechanisms, however, for gene/drug delivery, is the non-selective nanoneedle important for gene/drug delivery? The primary goal of using CNT is to exploit its
“nano-needle” property for a more efficient delivery, especially delivery of siRNA to
difficult-to transfect cells [6-8]. Nano-needle is one of many possible mechanisms for
utilizing CNT in gene/drug delivery. Regardless of the cellular entry mechanism, the use
of CNT for gene/drug delivery is justified based on the angle of enhancing the
bioavailability of gene/drug, at least for cancer [9-13]. Another question is whether the
non-selective cellular entry is harmful? In other words, would the CNT induce potential
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undesirable side effects if non-targeted cells or tissues were affected and how important
is it? As discussed briefly in chapter 1, the immunogenicity of CNT was demonstrated
but there are a lot of controversial reports on its toxicity. This is not covered intensively
in this thesis, it is not the focus of the thesis and a definite conclusion cannot be made.
According to the experimental data presented in this thesis, the cytoxicity of the CNT
depends on its functionalization. Indeed, the development of chapter 3 and chapter 4 were
based on the experience of chapter 2. The cytotoxicity of DGI/C is high and it would be
more preferable to have a delivery system with lower toxicity. Therefore, same as the
conclusion made in chapter 1, the cytotoxicity largely depends on the functionalization.
Also, it is believed that CNT does not naturally exist. Although there are reports on
neuron cells and various biological agents that are able to break down CNT [14-21], CNT
is not easy to be broken down compared to other polymers. Take poly(lactic acid) for
example, it can be broken down by hydrolysis therefore water is able to mediate the
degradation of poly(lactic acid). CNT still requires specific enzymes to break it down and
all of the reports so far use covalently modified CNT. It is more preferable for a
drug/gene delivery system to use a degradable CNT instead of non-degradable CNT.
However, it was also reported that CNT can be eliminated from the circulation [22, 23].
Therefore, the use of eliminable CNT instead of degradable CNT is more preferable
because of the intrinsic difficulty of CNT degradation. With the already developed
eliminable CNT, we are optimistic about the toxicity issue for utilizing CNT as a
systematic delivery vector.
Another criterion to consider is the type of siRNA it carries. For example, if the carried
siRNA is used to stop the proliferation of the cells, it may be harmful if it went to
reproductive organs. Another example is mTOR, mTOR is a well-studied gene which is
important for T cell differentiation [24-26], therefore its systematic down regulation
should be avoided unless it is the goal of the therapy. Alternatively, if the siRNA was to
stop the function of specific cells such that other cells didn’t express that molecule like
V600E Braf, it is harmless for non-selective delivery. Therefore, the selectivity and
specificity can also be fine-tuned by the type of siRNA delivered. The distribution of
CNT based delivery system found by other researchers was similar to what was found
and reported in chapter 2. We can see that the uptake mostly related to the size of the
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complexes, which, most of them ended up localizing in the liver and spleen. Therefore,
extra care should be taken for the use of siRNA which might alter the function of the
liver and spleen.
In chapter 3, IS/C was used for transdermal siRNA delivery. It is so far the first topical
siRNA delivery using CNT. Based on the promising results in chapter 3, the mechanism
of the transdermal behavior should further be characterized and tested in artificial human
skin. Also, the acute and chronic immune response of skin to IS/C should also be
characterized, which can be done in vitro using artificial human skin or a porcine ear skin
model by measuring the release of cytokine. The transdermal behavior can be tested with
Franz diffusion cell filled with PBS at pH 7.4 with temperature maintained at 37 oC. The
transdermal capacity can then be done by observing the Cy3-labelled siRNA with
fluorescence microscopy. Mice are not a good model for studying human skin
transdermal activity because of the different thicknesses in SC between mouse and
human as well as the diffusion coefficient [27].
In chapter 4, FGIS/C was used for systematic siRNA delivery. It is quite interesting that
there is no significant difference between the FGIS/C and GIS/C in in vitro siRNA uptake
for KB cells. One of the possible reasons is although the cell culture media of KB cells
were replaced by folate free media, the level of overexpression is still “low” such that the
difference cannot be seen in KB cells. As discussed in chapter 4, the suitability of culture
media might play a role, which might account for the difference. Further study on the
cells FA expression profile and behavior is needed to understand the difference.
Nevertheless, in vitro modelling is inadequate for mimicking in vivo environments and
the zeta potential, as well, the size of the complexes plays a more important role than the
others [28]. For the in vivo experiment, it would be great if the injection can be done
more frequently to see if there is a better therapeutic outcome, especially if it is possible
to see the difference between FGIS/C/si-mTOR and GIS/C/si-mTOR. It is well known
that gene silencing could last for around 7 days in actively dividing cells [29]. Therefore,
mTOR in tumors is not always down-regulated. A higher dose or more frequent treatment
can be used. Based on the existing data of siRNA localization as well as western blotting,
we believed that FGIS/C exhibit better tumor targeting ability while GIS/C is as effective
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based on other unknown factors. Certainly, if the localization of CNT to the tumor was
principally driven by the zeta potential of the complexes, the trend reported here,
including the localization of siRNA and down regulation of mTOR protein level should
be the same.

5.2

Future Prospect of CNT in siRNA Delivery

In this thesis, the novel non-covalent functionalization of CNT enables us to examine
various hypotheses as well as revealing the potential of utilizing CNT for siRNA
delivery. Based on some of the observations of the CNT studied, the following
modification can be carried out to tackle some of the problems faced in the siRNA
delivery system developed and reported in this thesis.
Based on the observation of IS/C, GIS/C and FGIS/C, the cytotoxicities are still high.
Therefore, reduction in toxicity could be beneficial and a shielding domain can be added
for reducing toxicity. A higher density of PEG and/or higher molecular weight of PEG
can be added to the PEI-SA polymer. Also, a mixture of various molecular weight of
PEG can be used. One of the loopholes is that PEG might actually reduce the binding of
PEI-SA to CNT, which might be overcome by using a sonicator with a higher power.
Another possible loophole is, over-functionalization, which would lead to low siRNA
binding and protection. This has to be carried out in a series of different ratios of PEI to
PEG as well as low molecular PEG to high molecular weight PEG.
Another approach is the synthesis of degradable PEI or other polycation [30-42].
Synthesis of lipid conjugated crosslinked PEI with disulphide bond for CNT dispersion
would be beneficial. The rationale is based on reducing the cytotoxicity of DGI/C. Low
molecular weight PEI has minimum cytotoxicity while high molecular weight PEI has
high transfection efficiency. Crosslinking low molecular weight PEI combines the low
cytotoxicity of low molecular weight PEI and the high transfection efficiency of high
molecular weight PEI. Also, crosslinked PEI can release the siRNA better than the
original PEI. Crosslinked PEI might have a worse CNT dispersing ability and thus a lipid
tail is more preferable for dispersing CNT. Also, the disulphide conjugated PEI will be
reduced specifically by the reduced-glutathione in cell [43, 44], therefore, the CNT can
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still be dispersed in water after it gained entry into the cell and releases the siRNA. The
first introduction of disulphide crosslinkers was done by Gosselin et al [45]. His idea is to
synthesize a biodegradable high molecular weight PEI with low molecular weight PEI for
pDNA delivery. If the crosslinkers or the bonds formed between the crosslinkers and PEI
are degradable, the crosslinked PEI would be suitable for systemic application.
Nonetheless, most of the crosslinked PEI have shown reduced cytotoxicity in the in vitro
experiment but the transfection efficiencies are usually similar to or are lower than that of
high molecular weight PEI. It has been reported that the transfection efficiencies of some
crosslinked PEI is higher than that of PEI 25 kDa and other commercially available
transfection reagents [46]. One of the possible loopholes of this system is that the
crosslinked PEI/CNT cannot condense siRNA due to reduced siRNA binding. If the
crosslinked PEI/CNT has a lower siRNA binding capacity, more hydrophobic lipid can
be attached to the PEI as to enhance the stability of the complexes as demonstrated by the
conjugation of an oleate tail to PEI600, PEI1200, or PEI1800 for siRNA delivery [47].
Covalent functionalization is more favorable than non-covalent functionalization of CNT
because the CNT will be more stable. Also, the degree of functionalization can be
controlled better than non-covalent approach. Various degrees of amination or attachment
of cationic oligomer can be carried out for testing the optimal cell penetrating effect or
transfection efficiency. However, it is more difficult to carry out and it is also possible
that the degree of functionalization can be so low such that it cannot carry siRNA or
protect siRNA effectively. Also, it is difficult to find a good solvent for dispersing both
the CNT and the groups to graft, thus, the functionalized CNT may suffer from lack of
homogeneity.
Finally, for the overall prospect of utilizing CNT as gene delivery vector. First of all,
most of the researchers are interested in the toxicity of CNT in the field of biology.
Recently, the toxicity of nanomaterials was uncovered and various mechanisms for
nanomaterials to induce toxicity [48, 49]. It is because of the increased surface area and
activity of the nano-sized surface. Indeed, most of the “effective” non-viral delivery
systems are too toxic to be used in vivo [50-53]. The toxicity issue of CNT is the core
concern of scientists as well as physicians, not to mention the efficacy of non-viral
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delivery system is still far behind the gene transfection rate of viruses. Second, the
intrinsic property of CNT is hydrophobic and it cannot bind to siRNA effectively.
Therefore, in theory, it is more preferable to use CNT for hydrophobic drug delivery than
siRNA or DNA delivery although CNT which can deliver siRNA or DNA can be used to
deliver hydrophobic drug at the same time. Third, the solubility of CNT is too low for
modification without specific equipment. Established experimental platforms for both
CNT modifications as well as in vitro and/or in vivo gene/siRNA delivery are necessary
before any discoveries could happen. It is one of the reasons why it hampers the overall
progress of research on CNT. Based on the studies covered by this thesis, however, noncovalent functionalization might serve as a way for early research and discovery and the
covalently functionalized CNT analogue might be synthesized for late stage research or
application.
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Appendix ii Animal Protocol
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" has been APPROVED by the Animal Use Subcommittee of the University
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Appendix iii Synthesis and characterization of DSPE-PEG-PLL and
DSPE-PEG-PLL/CNT (DGL/C), cellular uptake mechanism of DGL/C
Synthesis of DSPE-PEG-PLL (DGL) was carried out the same way as DSPE-PEG-PEI.
Briefly, 200 µL (1.75 µmol) of DSPE-PEG-COOH was added to a round bottom flask
and it was dried with compressed air. Then 5 mL DMSO and 10.6 mg (55.3 µmol) of
EDC was added. The mixture was stirred for 15 minutes and then desired amount of PLL
(Mw 8,000) solution in MES buffer (0.1 M, pH 5.5) was added. The reaction was allowed
to proceed overnight and then the reaction mixture was dialyzed (50k Da MWCO)
against deionized water for 48 hours. The product was then lyophilized for 2 days.
CNT was dispersed with a similar method with DGI/C. Briefly, 5 mg of DGL was
dissolved in water and then 5 mg of CNT was added. The mixture was sonicated for 1
hour and then the mixture was centrifuged at 24000g at 4 degree Celsius. The pellet was
discarded and the supernatant was concentrated with ultracentrifugation column. The
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Figure A 1 1H-NMR of DSPE-PEG-PLL
1

H-NMR of DSPE-PEG-PLL, the ratio between PLL and DSPE-PEG was found to be 1:6
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Figure A 2 Gel shift assay of DGL/C and siRNA
Gel shift assay of DGL/C and siRNA. The siRNA cond
condensation
ensation ratio is 1:10 (w/w,
DGI/C : siRNA)
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Figure A 3 Cellular uptake of DGL/C
B16-F10 cells were seeded 1.5x105 cells per well in 24 well plate. The cells were
transfected with DGL/C (1:1 w/w to siRNA) and lipofectamine 2000 (2µL) and Cy3labelled siRNA (0.5 µg) for 24 hours in serum containing media. The cells were
trypsinized and analysized with flow cytometry. The cellular uptake of DPL/C/siRNA is
2.8%.
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Appendix iv Cellular uptake mechanism determination
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Figure A 4 Cellular uptake of siRNA with energy depleted condition
Before the transfection, the cell media was replaced with fresh media, media with 0.005%
sodium azide or 0.05% sodium azide. Cells were then transfected with DGI/C 9 or PEI.
0.5 µg of Cy3-labeled siRNA and 2:1 (w/w) of PEI and 5:1 (w/w) of DGI/C 9 were used
for transfection. 4 hours after transfection, the cells were washed with cold PBS and were
trypsinized for flow cytometry analysis. PEI is well-known to gain into the cell by energy
depended mechanism. Also, it can escape from endosome effectively. The mechanism of
both transfection are energy depended because the siRNA uptake was reduced
significantly with the sodium azide concentration.
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Appendix v 1H-NMR
NMR spectrum of the compounds 1b
1b-1e,
1e, 2b,2c in
Chapter 4

Figure A 5 1H-NMR
NMR of 1b
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Figure A 6 1H-NMR of 1c
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NMR of 1d
Figure A 7 1H-NMR
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NMR of 1e
Figure A 8 1H-NMR
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NMR of 2b
Figure A 9 1H-NMR
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NMR of 2c
Figure A 10 1H-NMR
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